<!DOCTYPE html>

<html lang="en">
<!--[325696|cc|]--><head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>Gleevec: Side effects, generic, dosage, and more</title>
<meta property='og:url' content='https://www.medicalnewstoday.com/articles/325696.php'/>		<meta property="og:type" content="article"/>
		<meta property="og:site_name" content="Medical News Today"/>
		<meta property="og:title" content="Gleevec: Side effects, generic, dosage, and more"/>
					<meta property="og:description" content="Gleevec (imatinib) is a brand-name prescription medication. It’s used to treat certain types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It’s also used to treat certain types of skin cancer and gastrointestinal cancer. Learn about side effects and more."/>
			<meta name="description" content="Gleevec (imatinib) is a brand-name prescription medication. It’s used to treat certain types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It’s also used to treat certain types of skin cancer and gastrointestinal cancer. Learn about side effects and more."/>
						<meta property="og:image" content="https://cdn-prod.medicalnewstoday.com/structure/images/social/mnt_sharing.png"/>
					<meta property="fb:admins" content="1658973110"/>
		<meta property="fb:app_id" content="147184211975697"/>
					<meta itemprop="description" content="Gleevec (imatinib) is a brand-name prescription medication. It’s used to treat certain types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It’s also used to treat certain types of skin cancer and gastrointestinal cancer. Learn about side effects and more."/>
						<meta itemprop="image" content="https://cdn-prod.medicalnewstoday.com/structure/images/social/mnt_sharing.png"/>
					<meta name="twitter:domain" content="medicalnewstoday.com"/>
		<meta name="twitter:card" content="summary_large_image"/>
		<meta name="twitter:site" content="@mnt"/>
		<meta name="twitter:title" content="Gleevec: Side effects, generic, dosage, and more"/>
					<meta name="twitter:description" content="Gleevec (imatinib) is a brand-name prescription medication. It’s used to treat certain types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It’s also used to treat certain types of skin cancer and gastrointestinal cancer. Learn about side effects and more."/>
					<meta name="twitter:creator" content="@mnt"/>
					<meta name="twitter:image:src" content="https://cdn-prod.medicalnewstoday.com/structure/images/social/mnt_sharing.png"/>
			<META name="rating" content="general">
<META http-equiv="Cache-Control" content="no-cache">
<meta name="p:domain_verify" content="ca332f19ebf583ba72eff99cc210a982"/>
<meta name="msvalidate.01" content="65DAC77377665AE872AC660E37807BC6" />
<META http-equiv="bulletin-text" content="Copyright">

			<link rel="canonical" href="https://www.medicalnewstoday.com/articles/325696.php">
			
<link rel="shortcut icon" type="image/png" href="https://cdn-prod.medicalnewstoday.com/favicon.png">
<link rel="icon" sizes="32x32" href="https://cdn-prod.medicalnewstoday.com/favicon.ico">
<link rel="apple-touch-icon" type="image/png" href="https://cdn-prod.medicalnewstoday.com/apple-touch-icon.png">

	<link rel="alternate" type="application/rss+xml" title="Medical News Today - Health News Headlines RSS Feed" href="https://rss.medicalnewstoday.com/featurednews.xml">
	<link rel="alternate" type="application/json" title="Medical News Today - Health News Headlines JSON Feed" href="https://rss.medicalnewstoday.com/json/featurednews.json">
	
<meta http-equiv="x-dns-prefetch-control" content="on">
<link rel="preconnect dns-prefetch" href="//cdn-prod.medicalnewstoday.com" crossorigin>
<link rel="preconnect dns-prefetch" href="//cdn2.medicalnewstoday.com" crossorigin>


	<link rel="preload" as="font" crossorigin="crossorigin" href="/structure/fonts/ProximaNova/ProximaNova-ExtraBold.woff2">
	<link rel="preload" as="font" crossorigin="crossorigin" href="/structure/fonts/ProximaNova/ProximaNova-Light.woff2">
	<link rel="preload" as="font" crossorigin="crossorigin" href="/structure/fonts/ProximaNova/ProximaNova-Regular.woff2">


	<style>
		@font-face {
			font-family: 'ProximaNova';
			src: url('/structure/fonts/ProximaNova/ProximaNova-ExtraBold.woff2') format('woff2'),
			url('/structure/fonts/ProximaNova/ProximaNova-ExtraBold.woff') format('woff');
			font-weight:900;
			font-display: swap;}
		@font-face {
			font-family: 'ProximaNova';
			src: url('/structure/fonts/ProximaNova/ProximaNova-Light.woff2') format('woff2'),
			url('/structure/fonts/ProximaNova/ProximaNova-Light.woff') format('woff');
			font-weight:200;
			font-style:lighter;
			font-display: swap;}
		@font-face {
			font-family: 'ProximaNova';
			src: url('/structure/fonts/ProximaNova/ProximaNova-Regular.woff2') format('woff2'),
			url('/structure/fonts/ProximaNova/ProximaNova-Regular.woff') format('woff');
			font-weight:400;
			font-weight:normal;
			font-style:normal;
			font-display: swap;}

		@font-face {
			font-family: 'ProximaNova';
			src: url('https://cdn-prod.medicalnewstoday.com/structure/fonts/ProximaNova/ProximaNova-Bold.woff2') format('woff2'),
			url('https://cdn-prod.medicalnewstoday.com/structure/fonts/ProximaNova/ProximaNova-Bold.woff') format('woff');
			font-weight:600;
			font-weight:bold;
			font-style:bold;
			font-display: swap;}

		@font-face {
			font-family: 'Arnhem';
			src: url('https://cdn-prod.medicalnewstoday.com/structure/fonts/Arnhem/ArnhemPro-Bold.woff') format('woff');
			font-weight:600;
			font-weight:bold;
			font-style:bold;
			font-display: swap;}
	</style>





	
<link href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css" rel="stylesheet" integrity="sha384-wvfXpqpZZVQGK6TAh5PVlGOfQNHSoD2xbE+QkPxCAFlNEevoEH3Sl0sibVcOQVnN" crossorigin="anonymous">

					<link rel="stylesheet" href="https://cdn-prod.medicalnewstoday.com/structure/styles/out/mnt_default_redesign_7721.css?v=190904" type="text/css" media="all" />
		

		



					<link rel="stylesheet" href="https://cdn-prod.medicalnewstoday.com/structure/styles/out/mnt_print_redesign_7721.css?v=20181203" type="text/css" media="print">
				
		


<!--[if lt IE 9]>
<script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>

			<link rel="stylesheet" href="https://cdn-prod.medicalnewstoday.com/structure/styles/out/mnt_ie.css" type="text/css" media="all" />
	


	<![endif]-->
<!--[if IE 7]>

<script src="//ie7-js.googlecode.com/svn/version/2.1(beta4)/IE7.js"></script>
<![endif]-->	
<!--[if IE 9]>
<script src="//ie7-js.googlecode.com/svn/version/2.1(beta4)/IE9.js"></script>
<![endif]-->


<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=0.2, maximum-scale=2.0, user-scalable=1"><!--desktop-->


<noscript>
<link rel="stylesheet" href="https://cdn-prod.medicalnewstoday.com/structure/styles/styles_noscript.css" type="text/css" media="all" />	
</noscript>
<script type="text/javascript" >
			var glob_mntcookie = 1;
	  </script>
<script>

glob_JS=(typeof glob_JS === 'undefined')?{'GAInit':[],'GA':[],"ExternalJS":[],"AD":[]}:glob_JS;

glob_TrueOnGDPR=(glob_mntcookie!=1);

//if use GDPR is true, we need this flag to make sure ga queue can ber execute after ga is ready
glob_isGaReady=!glob_TrueOnGDPR;



if(typeof fireOrSaveGoogleAdFunctions === 'undefined'){



    function fireOrSaveGoogleAdFunctions(adFunction){

        if(!glob_TrueOnGDPR){

            adFunction();

        }else{

            if(typeof fireOrSaveGoogleADs === 'undefined'){
                //save ad event in queue
                glob_JS.AD.push(adFunction);
            }else{
                //let next function to determine save or fire ad function
                fireOrSaveGoogleADs(adFunction);

            }
        }

    }

    function fireOrSaveJsFunctions(jsType,jsFunction){

        if(!glob_TrueOnGDPR && jsType!=0){
            //if GDPR already accept, and func type is not ga event, just exec

            jsFunction()

        }else if(!glob_TrueOnGDPR && jsType===0) {
            //for ga event only

            if(glob_isGaReady) {
                //if ga ready, call the function
                jsFunction();
            }else{
                //if user accept GDPR, but ga not ready, still push new command into queue
                glob_JS.GA.push(jsFunction);

            }

        }else{

                if(jsType<0){
                    jsType='GAInit'
                }else if(jsType==0){
                    jsType='GA';
                }else{
                    jsType='ExternalJS';
                }

                if(typeof fireJS === 'undefined'){
                    //save ad event in queue


                    if(jsType=='GAInit'){

                        glob_JS.GAInit.push(jsFunction);

                    }else if(jsType=='GA') {

                        glob_JS.GA.push(jsFunction);
                    }else
                    {
                        //default is other js
                        glob_JS.ExternalJS.push(jsFunction);
                    }


                }else{
                    //let next function to determine save or fire ad function
                    fireJS(jsType,jsFunction);

                }
            }
    }



    function loadScript(url, parameters,callback){



        var script = document.createElement("script");
        script.type = "text/javascript";


        //add custom attribute
        for (var key in parameters) {
            if (parameters.hasOwnProperty(key)) {
                script.setAttribute(key,parameters[key]);
            }
        }


        if (script.readyState){  //IE
            script.onreadystatechange = function(){
                if (script.readyState == "loaded" ||
                    script.readyState == "complete"){
                    script.onreadystatechange = null;
                    callback();
                }
            };
        } else {  //Others
            script.onload = function(){

                if(typeof callback === 'function'){
                    callback();
                }

            };
        }

        script.src = url;
        document.getElementsByTagName("head")[0].appendChild(script);
    }



}

</script>




<!--<script type='text/javascript'>
(function() {
var useSSL = 'https:' == document.location.protocol;
var src = (useSSL ? 'https:' : 'http:') +
'//www.googletagservices.com/tag/js/gpt.js';
document.write('<scr' + 'ipt src="' + src + '"></scr' + 'ipt>');
})();
</script>-->


<script type="text/javascript">
	//CMP	
 	var isEEA = false;
 	var passEEACheck = false;

	var metadata = 'BOSk20WOSk20WABABBENBR-AAAAeCAFAAUABwAEAANABCA';
	var purposeConsents = { 1: true, 2: true, 3: true, 4: true, 5: true };
	var vendorConsents = { 10:true, 28: true, 32: true, 52: true, 132: true };

		function __cmp(cmd, p, cb) {
			if (cmd === 'getVendorConsents' || cmd === 'getConsentData') {
				cb({
					hasGlobalScope: true,
					gdprApplies: isEEA,
					metadata: metadata,
					consentData: metadata,
					purposeConsents: purposeConsents,
					vendorConsents: vendorConsents
				}, true);
			} else if (cmd === 'ping') {
				cb({gdprAppliesGlobally: false, cmpLoaded: isEEA});
			} else {
				throw new Error('Invalid CMP command '+ cmd);
			}
		}
</script>
<!-- <script async src="//js-sec.indexww.com/ht/p/184901-208206248649346.js"></script> -->
<!-- <script async src="//js-sec.indexww.com/ht/p/180447-192872210293780.js"></script> -->
<script type="text/javascript">
	fireOrSaveJsFunctions(1,function(){
		(function() {
			var indexWrapper = document.createElement("script");
			indexWrapper.async = true;
			indexWrapper.type = "text/javascript";
			var useSSL = "https:" == document.location.protocol;
			indexWrapper.src = (useSSL ? "https:" : "http:") + "//js-sec.indexww.com/ht/p/180447-192872210293780.js";
			var node =document.getElementsByTagName("script")[0];
			node.parentNode.insertBefore(indexWrapper, node);
		})();
	});
</script>
<script type="text/javascript">
fireOrSaveJsFunctions(1,function(){
	window.headertag = window.headertag || {};
	window.headertag.pagetype='drugs';
});
</script>

<script type="text/javascript">
	//ADBRIDG MIGRATION: Load the Adbridg library directly after the GPT library. 
  var AdBridg = AdBridg || {};
  AdBridg.cmd = AdBridg.cmd || [];
  window.adbridgFallback = function() {
		console.log('ADBRIDG MIGRATION: library failed to load; falling back to GPT');
    var dq = [], l = [], ls = {}, lf = [], es;
    var rl = function(f) {return function(){var a=arguments, x=function(){f.apply(null,a)};lf.push(x);pl()}}
    var pl = function() {if(!l.length){while(lf.length){(lf.shift())()}}}
    dq.process = function() { while(dq.length) { googletag.display(dq.shift()); }}
    AdBridg.defineSlot = function(p, s, d) { return googletag.defineSlot(p, s, d).addService(googletag.pubads()); }
    AdBridg.defineOutOfPageSlot = function(p, d) { return googletag.defineOutOfPageSlot(p, d).addService(googletag.pubads()); }
    AdBridg.destroySlots = function(s) { return googletag.destroySlots(s); }
    AdBridg.display = function(d) { dq.push(d); if (es) { dq.process(); }}
    AdBridg.refresh = function(s, o) { googletag.pubads().refresh(s, o); }
    AdBridg.render = function() { }
    AdBridg.serve = function() { googletag.enableServices(); es=1; dq.process(); }
    AdBridg.sizeMapping = function() { return googletag.sizeMapping(); }
    AdBridg.useSizeMapping = function() { }
    AdBridg.lock = function(s) {if(ls[s]){ls[s]=null;return;}l.push(s);pl()}
    AdBridg.unlock = function(s) {var f=0; for(var i=0;i<l.length;++i){if(l[i]==s){l.splice(i,1);f=1}}; if(!f){ls[s]=1} pl()}
		AdBridg.cmd.push = function(f) {
			if (typeof(f)=='object') {
				var api_fallback = function(o) {
					googletag.cmd.push(function() {
						var fl;
						if (o.gpt_path) {
							var u=AdBridg.defineSlot(o.gpt_path,o.size||[],o.dom_id);
							if(o.size_map) {
								var m = googletag.sizeMapping();
								for(var oi=0;oi<o.size_map.length;oi++){m=m.addSize(o.size_map[oi].viewport, o.size_map[oi].sizes);}
								u.defineSizeMapping(m.build());
							}
							if(o.events) {
								if(o.events["gpt.defined"]){o.events["gpt.defined"](u);}
								fl = function(a,b){if(o.events[a]){googletag.pubads().addEventListener(b,function(e){if(e.slot===u){o.events[a](u,e)}})}}
								fl("gpt.rendered",'slotRenderEnded');
								fl("gpt.viewed",'impressionViewable');
								fl("gpt.visibilityChanged",'slotVisibilityChanged');
							}
						} else if (o.events) {
							fl = function(a,b){if(o.events[a]){googletag.pubads().addEventListener(b,function(e){o.events[a](a,e)})}}
							fl("gpt.render_raw",'slotRenderEnded');
							fl("gpt.viewed_raw",'impressionViewable');
						}
					});
				}
				if(f.length){for(var i=0;i<f.length;++i){api_fallback(f[i]);}}else{api_fallback(f);}
				f=function(){AdBridg.serve()}
			}
			return googletag.cmd.push(f);
		}
		while (AdBridg.cmd.length) { AdBridg.cmd.push(AdBridg.cmd.shift()); }
  };
	fireOrSaveJsFunctions(1, function() {
		(function() {
	      var adb = document.createElement("script");
	      adb.async = true;
	      adb.type = "text/javascript";
	      adb.src = '//prod.adspsp.com/adb.2418030m.min.js';
	      var node = document.getElementsByTagName('script')[0];
	      node.parentNode.insertBefore(adb, node);

	      // Return control to GPT if the AdBridg library fails to load.
	      adb.onerror = function() {
	        if (AdBridg.exists) { return; }
	        document.createElement('IMG').src = '//adspsp.com/pt/2418030/3/1/?e=0';
	        window.adbridgFallback();
	      }
	  })();
	});
</script>

<!-- Load DFP -->
<script type="text/javascript">
	var googletag = googletag || { };
	googletag.cmd = googletag.cmd || [ ];
	fireOrSaveJsFunctions(1,function(){
		(function() {
			var gads = document.createElement("script");
			gads.async = true;
			gads.type = "text/javascript";
			var useSSL = "https:" == document.location.protocol;
			gads.src = (useSSL ? "https:" : "http:") + "//www.googletagservices.com/tag/js/gpt.js";
			var node =document.getElementsByTagName("script")[0];
			node.parentNode.insertBefore(gads, node);
		})();
	});
</script>

<!--New header bidding-->
<script>
var amzn_win=window,amzn_c=5,amzn_x=0;while(amzn_x<amzn_c){amzn_win=amzn_win.parent;if(amzn_win.apstag)try{amzn_win.apstag.renderImp(document,"%%PATTERN:amzniid%%");amzn_x=amzn_c}catch(e){}amzn_x++};
</script> 

<script type="text/javascript">
	fireOrSaveGoogleAdFunctions(function() {
		AdBridg.cmd.push(function () {
			// ADBRIDG MIGRATION: this command to set AdSense is one of the few
			// GPT commands that should not be replaced with our library proxy.
			googletag.pubads().set("adsense_background_color", "FFFFFF");
		});
	});
</script>


<script type="text/javascript">
	var googleDegfaultAdVars = {"main":"'cancer-oncology'","sub":"'blood', 'gastrointestinal', 'melanoma'","k1":"'leukemiacml'","k2":"'cancer'","k3":"'health'","uniq":"'325696'","msiteID":"'gleeveccdi'","msiteactive":"'True'","sponsoredPageNid":"''"};
	var googleAdSlotInfo = [];
	
	fireOrSaveGoogleAdFunctions(function(){
		AdBridg.cmd.push({
		  config: {
		    k1: googleDegfaultAdVars.k1 || "",
		    k2: googleDegfaultAdVars.k2 || ""
		  }
		});	
	});
	
</script>

<!-- End of old ads area -->
<script type='text/javascript'>
//Page level targeting setup
var adRPV = Math.floor(Math.random()*100)+1;
adRPV = adRPV.toString();

fireOrSaveGoogleAdFunctions(function(){
// ADBRIDG MIGRATION: the `cmd` function needs to run through AdBridg, but the
// setTargeting methods should stay native to GPT.
AdBridg.cmd.push(function() {
	googletag.pubads().setTargeting('rpv', adRPV);
	//We need to add a new key for 'url'
    googletag.pubads().setTargeting('url', encodeURI(location.pathname));

    //Set default targeting first
            if (typeof googleDegfaultAdVars !== "undefined") {
            for (var k in googleDegfaultAdVars) {
                if (k == "sub" || googleDegfaultAdVars[k].toString().indexOf(",") > -1) {
                    var finalOutput = googleDegfaultAdVars[k].split(',');
                    //Remove the single qoute
                    for (var i in finalOutput) {
                        if (finalOutput[i].trim().toString().indexOf("'") == 0) {
                            finalOutput[i] = finalOutput[i].trim().slice(1, -1);
                        } else {
    						finalOutput[i] = finalOutput[i].trim();
                        }
                    }
                } else {
                    if (googleDegfaultAdVars[k].toString().indexOf("'") == 0) {
                        //if it got single qoute inside, we remove it
                        var finalOutput = googleDegfaultAdVars[k].slice(1, -1);
                    } else {
                        var finalOutput = googleDegfaultAdVars[k];
                    }
                }
                googletag.pubads().setTargeting(k, finalOutput);
            }
        }
    	//googletag.pubads().enableAsyncRendering(); // enable async loading
	// Disable initial load, we will use refresh() to fetch ads.
	// Calling this function means that display() calls just
	// register the slot as ready, but do not fetch ads for it.
	// googletag.pubads().disableInitialLoad();
 //  	googletag.pubads().enableSingleRequest();
    // googletag.pubads().enableLazyLoad({
    //     fetchMarginPercent: 50,  // Fetch slots within 5 viewports.
    //     renderMarginPercent: 30,  // Render slots within 2 viewports.
    //     mobileScaling: 2.0  // Double the above values on mobile.
    // });
	// googletag.enableServices();
    // ADBRIDG MIGRATION: by default, we enable single request, disable initial
    // load, and async rendering is enabled by default (GPT no longer supports
    // synchronous rendering as of 2019-01-21.)
    // All we need to do now is tell AdBridg to begin serving the ads.
    // AdBridg.serve();
    // console.log("serve happened in page level");

});
});
</script>
<script>
// check viewport for resize events and reload ads (1000ms delay)
var resizeTimer;
var width = window.innerWidth;

function resizer() {
	//Check to see if the width is changed 
	var newWidth = window.innerWidth;
	if (width != newWidth) {
		// check if we've crossed a break point (only need to refresh if crossing the 1000px break point)
		if (width >= 1000 && newWidth < 1000) {
			
							// DECREASE IN WIDTH
				fireOrSaveGoogleAdFunctions(function() {
					AdBridg.cmd.push(function () {
						if (typeof window.DLB1 !== "undefined") {
							AdBridg.refresh([window.DLB1]);
						}
					});
				});
			
			// send resize+refresh event
			fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'Browser Width', eventAction: 'Resize / Shrink / Ad refresh', eventLabel: 'Resize / Shrink / Ad refresh'});});
			
		} else if (width < 1000 && newWidth >= 1000) {
			
			// INCREASE IN WIDTH
			// 
							if(typeof window.DLB1 !== "undefined"){
					AdBridg.refresh([window.DLB1]);	
				}
						
			// send resize+refresh event
			fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'Browser Width', eventAction: 'Resize / Grow / Ad refresh', eventLabel: 'Resize / Grow / Ad refresh'});});
			
		} else {
			// send resize event
			fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'Browser Width', eventAction: 'Resize / No ad refresh', eventLabel: 'Resize / No ad refresh'});});
		}
	}

	width = newWidth;
}

window.addEventListener("resize", function(){ 
	clearTimeout(resizeTimer);
	resizeTimer = setTimeout(resizer, 1000);
});

</script>

<!--New header bidding-->
<script>
		!function(a9,a,p,s,t,A,g){if(a[a9])return;function q(c,r){a[a9]._Q.push([c,r])}a[a9]={init:function(){q("i",arguments)},fetchBids:function(){q("f",arguments)},setDisplayBids:function(){},_Q:[]};A=p.createElement(s);A.async=!0;A.src=t;g=p.getElementsByTagName(s)[0];g.parentNode.insertBefore(A,g)}("apstag",window,document,"script","//c.amazon-adsystem.com/aax2/apstag.js");


		var initParams = {
			pubID: '3083',
			adServer: 'googletag'
		};


		fireOrSaveJsFunctions(1,function(){

			if (passEEACheck||(isEEA&&glob_mntcookie)) {
				__cmp('getConsentData', null, function(vendorConsentData, success) {
					
					initParams.gdpr = { enabled: true, consent: vendorConsentData.metadata };
					apstag.init(initParams);
				});
			} else {
				apstag.init(initParams);
			}

	 })

</script>

	


	<script type="text/javascript">
	this.top.location!==this.location&&(this.top.location=this.location);
	</script>
	<style>.async-hide { opacity: 0 !important} </style>
<script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date;
h.end=i=function(){s.className=s.className.replace(RegExp(' ?'+y),'')};
(a[n]=a[n]||[]).hide=h;setTimeout(function(){i();h.end=null},c);h.timeout=c;
})(window,document.documentElement,'async-hide','dataLayer',4000,
{'GTM-W59HFNJ':true});</script>

	<script type="text/javascript">

			<!-- GA Universal Code 2014-08 (obfuscated) -->

			eval(function(p,a,c,k,e,d){e=function(c){return(c<a?'':e(parseInt(c/a)))+((c=c%a)>35?String.fromCharCode(c+29):c.toString(36))};while(c--){if(k[c]){p=p.replace(new RegExp('\\b'+e(c)+'\\b','g'),k[c])}}return p}('5(-1,2(){(2(i,s,o,g,r,a,m){i[\'c\']=r;i[r]=i[r]||2(){(i[r].q=i[r].q||[]).e(d)},i[r].l=1*j h();a=s.b(o),m=s.6(o)[0];a.7=1;a.8=g;m.9.k(a,m)})(y,A,\'z\',\'//x.n-3.t/3.u\',\'4\')});5(-1,2(){4(\'v\',\'p-w-1\',\'f\')});',37,37,'||function|analytics|ga|fireOrSaveJsFunctions|getElementsByTagName|async|src|parentNode||createElement|GoogleAnalyticsObject|arguments|push|auto||Date||new|insertBefore|||google||UA||||com|js|create|849615|www|window|script|document'.split('|')))


	</script>
		<script type="text/javascript">
	/*
	CSS Browser Selector v0.4.0 (Nov 02, 2010)
	Rafael Lima (http://rafael.adm.br)
	http://rafael.adm.br/css_browser_selector
	License: http://creativecommons.org/licenses/by/2.5/
	Contributors: http://rafael.adm.br/css_browser_selector#contributors
	*/
	function css_browser_selector(u){var ua=u.toLowerCase(),is=function(t){return ua.indexOf(t)>-1},g='gecko',w='webkit',s='safari',o='opera',m='mobile',h=document.documentElement,b=[(!(/opera|webtv/i.test(ua))&&/msie\s(\d)/.test(ua))?('ie ie'+RegExp.$1):is('firefox/2')?g+' ff2':is('firefox/3.5')?g+' ff3 ff3_5':is('firefox/3.6')?g+' ff3 ff3_6':is('firefox/3')?g+' ff3':is('gecko/')?g:is('opera')?o+(/version\/(\d+)/.test(ua)?' '+o+RegExp.$1:(/opera(\s|\/)(\d+)/.test(ua)?' '+o+RegExp.$2:'')):is('konqueror')?'konqueror':is('blackberry')?m+' blackberry':is('android')?m+' android':is('chrome')?w+' chrome':is('iron')?w+' iron':is('applewebkit/')?w+' '+s+(/version\/(\d+)/.test(ua)?' '+s+RegExp.$1:''):is('mozilla/')?g:'',is('j2me')?m+' j2me':is('iphone')?m+' iphone':is('ipod')?m+' ipod':is('ipad')?m+' ipad':is('mac')?'mac':is('darwin')?'mac':is('webtv')?'webtv':is('win')?'win'+(is('windows nt 6.0')?' vista':''):is('freebsd')?'freebsd':(is('x11')||is('linux'))?'linux':'','js']; c = b.join(' '); h.className += ' '+c; return c;}; css_browser_selector(navigator.userAgent);
	</script>
	<script type="text/javascript">
var viewportWidth = Math.max(document.documentElement.clientWidth, window.innerWidth || 0);
var viewportHeight = Math.max(document.documentElement.clientHeight, window.innerHeight || 0);

	switch (true) {
		case viewportWidth > 1360:
			var viewportBreakpoint = 'Desktop - XL';
			break;
		case viewportWidth > 1200:
			var viewportBreakpoint = 'Desktop - L';
			break;
		case viewportWidth > 1000:
			var viewportBreakpoint = 'Desktop - M';
			break;
		default:
			var viewportBreakpoint = 'Desktop - S';
	}
	
fireOrSaveJsFunctions(0,function() {ga('set', 'dimension20', viewportBreakpoint);});

var existUserId=false;
var vanillaAjax=function(url,httpMethod,data,headerJsonString){

	var request = new XMLHttpRequest();


	request.open(httpMethod, url, true);


	//set header if exist
	try{
		var headerObj=JSON.parse(headerJsonString);

		for (var headerName in headerObj) {

			//optional check for properties from prototype chain
			if (headerObj.hasOwnProperty(headerName)) {
				//no a property from prototype chain

				var headerValue = headerObj[headerName];
				request.setRequestHeader(headerName,headerValue);

			}
		}

	}catch(e){
		console.log("Set datadog api header failed");
		//don't set header if something wrong;
	}




	request.onload = function() {

		if (request.status >= 200 && request.status < 400) {
			// Success!
			var resp = request.responseText;

		} else {
			// We reached our target server, but it returned an error

		}
	};

	request.onerror = function() {
		// There was a connection error of some sort
	};

	request.send(data);

};



function getUrlVars(targetField) {
	var vars = {};
	var parts = window.location.href.replace(/[?&]+([^=&]+)=([^&]*)/gi,
	function(m,key,value) {
		vars[key] = value;
	});

	if(typeof vars[targetField] !== "undefined"){

		return vars[targetField];

	}else{

		return "";
 	}

}


fireOrSaveJsFunctions(0,function() {ga('set', 'dimension35', getUrlVars("tc"));});
fireOrSaveJsFunctions(0,function() {ga('set', 'dimension36', getUrlVars("subid"));});
fireOrSaveJsFunctions(0,function() {ga('set', 'dimension37', getUrlVars("subid2"));});
fireOrSaveJsFunctions(0,function() {ga('set', 'dimension38', getUrlVars("apsid"));});


//set dimension34 value if exist

if(existUserId){

	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension34', existUserId);});

}else if(getUrlVars("apid")){

	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension34', getUrlVars("apid"));});

	vanillaAjax("/account/message-session-setter.php","POST","activation_platform_user_id="+getUrlVars("apid"),"{\"Content-type\":\"application/x-www-form-urlencoded\"}");

}

//will be called from newsletter register.
function setUserId(userId){

ga('set', 'dimension34', ""+userId);

}

fireOrSaveJsFunctions(0,function() {ga('set', 'dimension40', 'Catherine C. Peng, PharmD, BCPS');});
		

fireOrSaveJsFunctions(0,function() {ga('set', {
'dimension1': "no",
'dimension2': "drugs_tabbed",
'dimension3': "Cancer / Oncology",
'dimension5': "month",
'dimension6': "desktop",
'dimension12': "2019-08-15",
'dimension17': "7721",
'dimension21': "2",
'dimension23': "Lindsay Slowiczek, PharmD",
'dimension24': "Blood / Hematology",
'dimension25': "GastroIntestinal / Gastroenterology",
'dimension26': "Melanoma / Skin Cancer",
'dimension27': "1",
'dimension28': "leukemiacml",
'dimension29': "cancer"
});});

if (window.devicePixelRatio) {
	var pixelRatio = (window.devicePixelRatio >= 1.5) ? "HiDPI" : "1X";
	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension7', pixelRatio);});
}

	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension10', viewportWidth);});
	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension11', viewportHeight);});
	
	var MNT_ga_paramKey = (document.location.search.indexOf('?') > -1 ? '&' : '?');
	var MNT_ga_url_msId_fragment = MNT_ga_paramKey + 'gaPage=[gleeveccdi]';  
	var MNT_ga_url_msId = document.location.pathname + document.location.search + MNT_ga_url_msId_fragment;
	
		fireOrSaveJsFunctions(0,function() {ga('set', 'page', MNT_ga_url_msId);});
	fireOrSaveJsFunctions(0,function() {ga('set', 'dimension16', 'gleeveccdi');});fireOrSaveJsFunctions(0,function() {ga('require', 'GTM-W59HFNJ');});
fireOrSaveJsFunctions(0,function() {ga('send', 'pageview');});

setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 030','325696')});",30000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 050','325696')});",50000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 070','325696')});",70000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 090','325696')});",90000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 110','325696')});",110000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 130','325696')});",130000)
setTimeout("fireOrSaveJsFunctions(0,function() {ga('send','event','Engagement Time','Engagement 150','325696')});",150000)
</script>
<script>
	fireOrSaveJsFunctions(1,function() {

		var _qevents = _qevents || [];

		(function() {
			var elem = document.createElement('script');
			//elem.src = (document.location.protocol == "https:" ? "https://secure" : "http://edge") + ".quantserve.com/quant.js";
			elem.src = "https://cdn-prod.medicalnewstoday.com/structure/javascript/cache/quant.js";
			elem.async = true;
			elem.type = "text/javascript";
			var scpt = document.getElementsByTagName('script')[0];
			scpt.parentNode.insertBefore(elem, scpt);
		})();

		_qevents.push({
			qacct:"p-v03RmX3GES6RT"
		});
	});


</script>

<script>
	fireOrSaveJsFunctions(1,function() {

		window._comscore = window._comscore || [];
		window._comscore.push({ c1: "2", c2: "19983957" });
		(function() {
			var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
			//s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
			s.src = "https://cdn-prod.medicalnewstoday.com/structure/javascript/cache/beacon.js";
			el.parentNode.insertBefore(s, el);
		})();

	})

</script>
<noscript>
  <img class="no_js" src="https://sb.scorecardresearch.com/p?c1=2&c2=19983957&cv=2.0&cj=1" />
</noscript>

<script>


	fireOrSaveJsFunctions(1,function() {

		!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
			n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
			n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
			t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
			document,'script','https://connect.facebook.net/en_US/fbevents.js');

		fbq('init', '1039134266174910');
		fbq('track', "PageView");

		fbq('track', 'ViewContent');

	});


</script>

<noscript><img height="1" width="1" style="display:none"
src="https://www.facebook.com/tr?id=1039134266174910&ev=PageView&noscript=1"
/></noscript>

<!-- Source: /controltag?confid=qqeynsltk&site=medical%20news%20today&edit=1 -->
<script class="kxct" data-id="qqeynsltk" data-timing="async" data-version="1.9" type="text/javascript">
	fireOrSaveJsFunctions(1,function() {
		window.Krux || ((Krux = function () {
			Krux.q.push(arguments)
		}).q = []);
		(function () {
			var k = document.createElement('script');
			k.type = 'text/javascript';
			k.async = true;
			var m, src = (m = location.href.match(/\bkxsrc=([^&]+)/)) && decodeURIComponent(m[1]);
			k.src = /^https?:\/\/([a-z0-9_\-\.]+\.)?krxd\.net(:\d{1,5})?\//i.test(src) ? src : src === "disable" ? "" :
			(location.protocol === "https:" ? "https:" : "http:") + "//cdn.krxd.net/controltag?confid=qqeynsltk";
			var s = document.getElementsByTagName('script')[0];
			s.parentNode.insertBefore(k, s);
		}());
	});
</script>


<!-- Hotjar Tracking Code for https://www.medicalnewstoday.com/ -->
<script>
	(function(h,o,t,j,a,r){
		h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
		h._hjSettings={hjid:1295463,hjsv:6};
		a=o.getElementsByTagName('head')[0];
		r=o.createElement('script');r.async=1;
		r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
		a.appendChild(r);
	})(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
</script>
<script type="text/javascript"> window.jstag=function(){function t(t){return function(){return t.apply(this,arguments),this}}function n(){var n=["ready"].concat(c.call(arguments));return t(function(){n.push(c.call(arguments)),this._q.push(n)})}var i={_q:[],_c:{},ts:(new Date).getTime(),ver:"2.0.0"},c=Array.prototype.slice;return i.init=function(t){return i._c=t,t.synchronous||i.loadtagmgr(t),this},i.loadtagmgr=function(t){var n=document.createElement("script");n.type="text/javascript",n.async=!0,n.src=t.url+"/api/tag/"+t.cid+"/lio.js";var i=document.getElementsByTagName("script")[0];i.parentNode.insertBefore(n,i)},i.ready=n(),i.send=n("send"),i.mock=n("mock"),i.identify=n("identify"),i.pageView=n("pageView"),i.bind=t(function(t){i._q.push([t,c.call(arguments,1)])}),i.block=t(function(){i._c.blockload=!0}),i.unblock=t(function(){i._c.blockload=!1}),i}(),window.jstag.init({cid:"107d418c4b7bb3debf57a3af0ce16190", url:"//c.lytics.io", min:true, loadid:false}); </script>

<!-- Facebook Pixel Code -->
<script>

	fireOrSaveJsFunctions(1,function() {

		!function (f, b, e, v, n, t, s) {
			if (f.fbq)return;
			n = f.fbq = function () {
				n.callMethod ?
					n.callMethod.apply(n, arguments) : n.queue.push(arguments)
			};
			if (!f._fbq)f._fbq = n;
			n.push = n;
			n.loaded = !0;
			n.version = '2.0';
			n.queue = [];
			t = b.createElement(e);
			t.async = !0;
			t.src = v;
			s = b.getElementsByTagName(e)[0];
			s.parentNode.insertBefore(t, s)
		}(window,
			document, 'script', 'https://connect.facebook.net/en_US/fbevents.js');

		fbq('init', '1039134266174910');
		fbq('track', "PageView");
	});
</script>

<noscript><img height="1" width="1" style="display:none"
src="https://www.facebook.com/tr?id=1039134266174910&ev=PageView&noscript=1"
/></noscript>



<!--Moat content code-->
<script>

	fireOrSaveJsFunctions(1,function(){

		(function(){function t(){for(var a=[8],e=1;2>=e;e++)a.push(8+e),a.push(8-e);a=a[Math.floor(Math.random()*a.length)];return{b:a,a:0==Math.floor(Math.random()*a)}}function k(a){var e=a=a.replace(":","");try{for(var b=0;100>b&&(a=decodeURIComponent(a),e!=a)&&!a.match(/^http(s)?\:/);b++)e=a}catch(c){}return a.replace(/(^\s+|\s+$)/g,"")}try{if(!location||!location.hostname||!location.pathname)return!1;var c=document.location.hostname.replace(/^www\./,""),u=function(){for(var a,b=document.getElementsByTagName("meta"),c,d=0,f=b.length;d<f;d++)if(c=b[d],"og:title"===c.getAttribute("property")){a=c.getAttribute("content");break}a||(a=document.title||"Untitled");return a}(),b={},b=function(a,b,c){a.l1=b;a.l2=c;a.l3="__page__";a.l4="-";return a}(b,c,u),l=(new Date).getTime(),m=Math.floor(Math.random()*Math.pow(10,12)),d,f;f=t();f.a?d=f.b:d=0;b.zmoatab_cm=d;b.t=l;b.de=m;b.zMoatAB_SNPT=!0;var g;d?g=d:g=1;var n;n=f?f.a?!0:!1:!0;var c=[],p=[k(b.l1),k(b.l2),k(b.l3),k(b.l4)].join(":"),v="https://wve3oiypgri4-a.akamaihd.net/z.gif?e=17&d="+
			encodeURIComponent(p)+"&de="+m+"&t="+l+"&i=HEALTHLINECONTENT1&cm="+g+"&mp=1&ac=1&pl=1&bq=10&vc=2&cs=0",w="https://px.moatads.com/pixel.gif?e=17&d="+encodeURIComponent(p)+"&de="+m+"&t="+l+"&i=HEALTHLINECONTENT1&cm="+g+"&mp=0&ac=1&pl=1&bq=10&ad_type=img&vc=2&cs=0",x="https://px.moatads.com/pixel.gif?e=17&d="+encodeURIComponent(p)+"&de="+m+"&t="+l+"&i=HEALTHLINECONTENT1&cm="+g+"&ku=1&ac=1&pl=1&bq=10&ad_type=img&vc=2&cs=0";n&&((new Image).src=v,(new Image).src=w);for(var q in b)c.push(q+"="+encodeURIComponent(b[q]));
			var c=c.join("&"),c=c+"&vc=2",h=document.createElement("script");h.type="text/javascript";h.async=!0;n&&(h.onerror=function(){(new Image).src=x});var r=document.getElementsByTagName("script")[0];r.parentNode.insertBefore(h,r);h.src="https://z.moatads.com/healthlinecontent451781663455/moatcontent.js#"+c}catch(a){try{var y="//pixel.moatads.com/pixel.gif?e=24&d=data%3Adata%3Adata%3Adata&i=MOATCONTENTABSNIPPET1&vc=2&ac=1&k="+encodeURIComponent(a)+"&j="+encodeURIComponent(document.referrer)+"&cs="+(new Date).getTime();
			(new Image).src=y}catch(e){}}})();


	});

</script>
</head>
<body id="drugs" class="article v2 tabbed lang_en">
<div itemscope="" itemtype="http://schema.org/NewsArticle">








<noscript>
<div class="header_message enable_js error">
<p>For full functionality, it is necessary to enable JavaScript. Here are <a href="http://www.enable-javascript.com" rel="noopener noreferrer" target="_blank">instructions how to enable JavaScript</a> in your web browser.</p>
</div>


<div class="fullscreen_outer">
	<div class="fullscreen_inner">
		<h5>Welcome to Medical News Today</h5>
		<p>
			Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a <a href="https://www.medicalnewstoday.com/privacy-policy#vendors" target="_blank">current list</a>) using cookies and similar automatic collection tools in order to a) personalize content and/or offers on our site or other sites, b) communicate with you upon request, and/or c) for additional reasons upon notice and, when applicable, with your consent.</p>
		<p>
			Healthline Media, Inc. is based in and operates this site from the United States. Any data you provide will be primarily stored and processed in the United States, pursuant to the laws of the United States, which may provide lesser privacy protections than European Economic Area countries.
		</p>
		<p>
			By clicking “accept” below, you acknowledge and grant your consent for these activities unless and until you withdraw your consent using our <a href="https://www.healthline.com/rights-request" rel="noopener noreferrer" target="_blank">rights request form</a>. Learn more in our <a href="https://www.medicalnewstoday.com/privacy-policy" target="_blank">Privacy Policy</a>.
		</p>
	</div>
</div>


</noscript>
<div id="header_message" class="new_menu">
<input type="hidden" id="is_usermobile" name="is_usermobile" value="0">





 
</div>

<div id="navigation" class="container default_menu new_menu">

	<div class="row">

		<nav role="navigation" class="main_nav">
		
			<ul class="main_nav left"> 	
				<li class="menu_topics">
					<a href="#"></a>
		
					
<div class="menu_panel fullscreen_outer topics">
  <div class="menu_panel fullscreen_inner">
    <div class="row">
					
					
					<div class="topics">
												
							<div class="menu_topic_container">
							
								<ul class="topic_headings">
									<li class="topic_headings_top"><span>Top categories</span>
										<ul class="topic_popular_list">
											<li><a href="/categories/blood">Blood / Hematology</a></li>
<li><a href="/categories/bones">Bones / Orthopedics</a></li>
<li><a href="/categories/breast_cancer">Breast Cancer</a></li>
<li><a href="/categories/colorectal_cancer">Colorectal Cancer</a></li>
<li><a href="/categories/depression">Depression</a></li>
<li><a href="/categories/gastrointestinal">GastroIntestinal</a></li>
<li><a href="/categories/hypertension">Hypertension</a></li>
<li><a href="/categories/lymphoma">Lymphoma</a></li>
<li><a href="/categories/mens_health">Men's Health</a></li>
<li><a href="/categories/neurology">Neurology / Neuroscience</a></li>
<li><a href="/categories/nutrition-diet">Nutrition / Diet</a></li>
<li><a href="/categories/pain">Pain / Anesthetics</a></li>
<li><a href="/categories/prostate">Prostate / Prostate Cancer</a></li>
<li><a href="/categories/psoriasis">Psoriasis</a></li>
<li><a href="/categories/respiratory">Respiratory</a></li>
<li><a href="/categories/sexual_health">Sexual Health / STDs</a></li>
<li><a href="/categories/stroke">Stroke</a></li>
<li><a href="/categories/tuberculosis">Tuberculosis</a></li>
<li><a href="/categories/urology-nephrology">Urology / Nephrology</a></li>
<li><a href="/categories/womens_health">Women's Health</a></li>
										</ul> 	
									</li>
																											
									<li class="topic_headings_all"><span>All categories</span>
										<ul class="topic_all_list">
											<li><a href="/categories#a">A - B</a></li>
											<li><a href="/categories#c">C - D</a></li>
											<li><a href="/categories#e">E - G</a></li>
											<li><a href="/categories#h">H - L</a></li>
											<li><a href="/categories#m">M - O</a></li>
											<li><a href="/categories#p">P - R</a></li>
											<li><a href="/categories#s">S - Z</a></li>
											<li><a href="/categories">All Topics</a></li>
										</ul>	
									</li>


								</ul> 									
							</div> 	
						
							<div class="menu_cta_container">
							
									<span>More</span>	
																		
									<ul class="topic_more_list">
										<li class="menu_newsletter_cta"><a href="#" class="new_reg_signup menu_item_link" data-signup-source="menu_item_link"><span class="icon_container"></span>Sign up for our newsletter</a></li>
										<li class="menu_discover_cta"><a href="/knowledge-center"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-menu-cta-2017.png" height="15" width ="34"/>Discover in-depth, condition specific articles written by our in-house team.</a></li>

									</ul> 	
	
							</div> 	
			
			
											
					</div> 	
					</div> 	
					</div> 	
											
											
											
					</div> 	
			  
				</li> 	

					<li class="menu_newsletter">

						<a href="#" data-signup-source="menu_newsletter_link" class="menu-newsletter-link  new_reg_signup"><div>Newsletter</div></a>

					</li> 	

			</ul>
				
			<div class="logo">
				<a href="/" accesskey="h" title="Medical News Today : Home">
					<img src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-2017-640-60.png" alt="MNT home">
					<p>MNT - Hourly Medical News Since 2003</p>
				</a>
			</div> 	
				
			<ul class="main_nav right"> 	

			<div id="search_area">


<div id="searchwrapper" class="">



<div class="search_trigger">

<form id="searchFormHeader" action="/search" >
<input type="text" id="header_search" placeholder="" class="searchbox" name="q" maxlength="150" autocomplete="off"/>
<button class="screen_only black float_right" id="header_search_button" type="submit" id="" title="Search MNT" value="">Search</button>
<button class="mobile_only blue float_right" id="header_search_button" type="submit" title="Search MNT" value="">Go</button>
<input type="hidden" name="p" value="1" />
</form>



</div>
	

</div>
</div>	
			


					<li class="menu_login">
						<a href="#" id="menu_login_link">
							<div>

							</div>
						</a>
					</li>
			</ul>
		</nav>	

	</div> 	

</div> 
<div id="navigation_scroll" class="container light  ">

<div class="row">

<nav id="subnavigation">

			<ul class="main_nav left"> 	
				<li class="menu_topics">
					<a href="#"></a>
		
					
<div class="menu_panel fullscreen_outer topics">
  <div class="menu_panel fullscreen_inner">
    <div class="row">
					
					
					<div class="topics">
												
							<div class="menu_topic_container">
							
								<ul class="topic_headings">
									<li class="topic_headings_top"><span>Top categories</span>
										<ul class="topic_popular_list">
											<li><a href="/categories/blood">Blood / Hematology</a></li>
<li><a href="/categories/bones">Bones / Orthopedics</a></li>
<li><a href="/categories/breast_cancer">Breast Cancer</a></li>
<li><a href="/categories/colorectal_cancer">Colorectal Cancer</a></li>
<li><a href="/categories/depression">Depression</a></li>
<li><a href="/categories/gastrointestinal">GastroIntestinal</a></li>
<li><a href="/categories/hypertension">Hypertension</a></li>
<li><a href="/categories/lymphoma">Lymphoma</a></li>
<li><a href="/categories/mens_health">Men's Health</a></li>
<li><a href="/categories/neurology">Neurology / Neuroscience</a></li>
<li><a href="/categories/nutrition-diet">Nutrition / Diet</a></li>
<li><a href="/categories/pain">Pain / Anesthetics</a></li>
<li><a href="/categories/prostate">Prostate / Prostate Cancer</a></li>
<li><a href="/categories/psoriasis">Psoriasis</a></li>
<li><a href="/categories/respiratory">Respiratory</a></li>
<li><a href="/categories/sexual_health">Sexual Health / STDs</a></li>
<li><a href="/categories/stroke">Stroke</a></li>
<li><a href="/categories/tuberculosis">Tuberculosis</a></li>
<li><a href="/categories/urology-nephrology">Urology / Nephrology</a></li>
<li><a href="/categories/womens_health">Women's Health</a></li>
										</ul> 	
									</li>
																											
									<li class="topic_headings_all"><span>All categories</span>
										<ul class="topic_all_list">
											<li><a href="/categories#a">A - B</a></li>
											<li><a href="/categories#c">C - D</a></li>
											<li><a href="/categories#e">E - G</a></li>
											<li><a href="/categories#h">H - L</a></li>
											<li><a href="/categories#m">M - O</a></li>
											<li><a href="/categories#p">P - R</a></li>
											<li><a href="/categories#s">S - Z</a></li>
											<li><a href="/categories">All Topics</a></li>
										</ul>	
									</li>

								</ul> 									
							</div> 	
						
							<div class="menu_cta_container">
							
									<span>More</span>	
																		
									<ul class="topic_more_list">

										<li class="menu_newsletter_cta"><a href="#" class="new_reg_signup menu_item_link" data-signup-source="menu_item_link"><span class="icon_container"></span>Sign up for our newsletter</a></li>
										<li class="menu_discover_cta"><a href="/knowledge-center"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-menu-cta-2017.png" height="15" width ="34"/>Discover in-depth, condition specific articles written by our in-house team.</a></li>

									</ul> 	
	
							</div> 	
			
			
											
					</div> 	
					</div> 	
					</div> 	
											
											
											
					</div> 	
			  
				</li> 

					<li class="menu_newsletter">

						<a href="#" data-signup-source="menu_newsletter_link" class="menu-newsletter-link  new_reg_signup"><div>Newsletter</div></a>

					</li> 
				
			</ul>
				
			<div class="logo">
				<a href="/" accesskey="h" title="Medical News Today : Home">
					<img src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-2017-640-60.png" alt="MNT home">
					<p>MNT - Hourly Medical News Since 2003</p>
				</a>
			</div> 	
				
			<ul class="main_nav right"> 	
				
					

			<div id="search_area">


<div id="searchwrapper" class="">



<div class="search_trigger">

<form id="searchFormHeader" action="/search" >
<input type="text" id="header_search" placeholder="" class="searchbox" name="q" maxlength="150" autocomplete="off"/>
<button class="screen_only black float_right" id="header_search_button" type="submit" id="" title="Search MNT" value="">Search</button>
<button class="mobile_only blue float_right" id="header_search_button" type="submit" title="Search MNT" value="">Go</button>
<input type="hidden" name="p" value="1" />
</form>



</div>
	

</div>
</div>	
			


					<li class="menu_login">
						<a href="#" id="menu_login_link">
							<div>

							</div>
						</a>

					</li>
			</ul>
		
		</nav>	

	</div> 	

</div> <div class="modal fade" id="picModal" tabindex="-1" role="dialog" style="z-index: 1040; padding-left:0;">
	<div class="modal-dialog" role="document">
		<div class="modal-content" style="">
			<div class="modal-header">
				<button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>

			</div>
			<div class="modal-body" style="text-align: center;">

				<div id="picModal-loading-animation">

					<i class="fa fa-circle-o-notch fa-spin fa-3x fa-fw"></i>
					<span class="sr-only">Loading...</span>

				</div>


				<span class="helper" style="display: inline-block;height: 100%;vertical-align: middle;"></span> <img id="origin-img" src="">

			</div>

		</div>
	</div>
</div>


<div class="modal fade site_modal modal_gdpr" tabindex="-1" role="dialog" aria-hidden="true" id="gdprModal" data-backdrop="static" data-keyboard="false">
	<div class="modal-dialog" role="document">

		<div class="modal-content">

			<div class="modal-header">
			</div>

			<div class="modal-body container" onscroll="modalScroll()">
				<div class="fullscreen_outer article_header">
					<div class="fullscreen_inner">
						<h5>Please accept our privacy terms</h5>
						<p>
							We use cookies and similar technologies to improve your browsing experience, personalize content and offers, show targeted ads, analyze traffic, and better understand you. We may share your information with third-party partners for marketing purposes. To learn more and make choices about data use, visit our <a href="https://www.medicalnewstoday.com/advertising" target="_blank">Advertising Policy</a> and <a href="https://www.medicalnewstoday.com/privacy-policy" target="_blank">Privacy Policy</a>. By clicking “Accept and Continue” below, (1) you consent to these activities unless and until you withdraw your consent using our rights request form, and (2) you consent to allow your data to be transferred, processed, and stored in the United States.
						</p>
					</div>
				</div>
			</div>
			<div class="modal-footer container gradient">
				<div class="article_header">
					<button class="primary" onclick="GDPRAccept()">ACCEPT AND CONTINUE TO SITE</button>
					<button class="secondary" onclick="confirmDeny()">Deny permission</button>
				</div>
			</div>

		</div>
		<div class="scroll_more hidden">
			<button class="primary" onclick="scrollAccept()">Scroll to Accept</button>
		</div>

	</div>
</div>



	<!--for new newsletter sign up proc-->
	<div class="modal fade registration_modal_form" tabindex="-1" role="dialog" aria-hidden="true" id="registrationModal">
		<div class="modal-dialog" role="document">
			<div class="modal-content modal_reg" id="registration_modal_form">
									<div class="modal-header screen_only">
						<h4 class="modal-title">Get the MNT newsletter</h4>
						<button type="button" class="close" data-dismiss="modal"></button>
					</div>
				


				<div class="modal-body" id="registration_start">

					<div class="iframe_scroll_container">

						<!--form migration start-->

						<form id="new-reg-form">
							<div class="form container_reg">
								<div class="form header_reg">

									<div class="form-group">
										<input type="email" name="formEmail" style="margin-bottom: 20px;" class="form-control newsletterFormEmail" id="inputEmail" placeholder="Enter email address" value="">
									</div>

									<!--error meesage place holder-->
									<div id="signFinishErrorHolder" class="errorHolder"></div>


									<div id="registration_modal_message" class="form-group">


										<!--while user finish the register process, something info need to tell user, but not error message-->
										<div id="newsletterRegisterInfo" class="message start">

										</div>


										<!--User will see the message everytime open the register modal-->
										<div id="newsletterTypeMessage" class="message start">

											<p>
												Enter your email address to subscribe to <span id="selectedCategoryText">our most top categories</span>
											</p>

											

<p>Your <a href="/privacy-policy" title="Privacy policy">privacy</a> is important to us.</p>

										</div>

									</div>

								</div>
							</div>

							<!--set by js-->
							<input type="hidden" id="newsletterCategories" name="newsletterCategories" value="">
							<input type="hidden" id="newsletterTypeMessageHTMLBackup" name="newsletterTypeMessageHTMLBackup" value="">

						</form>

						<!--form migration end-->

					</div>
				</div>


				<div class="modal-footer">
					<button type="button" id="email-start-signup-btn" class="btn btn-success btn-block">CONTINUE</button>

<!--					<button type="button" id="email-finish-signup-btn" class="btn btn-danger btn-block" data-dismiss="modal">OK</button>-->
				</div>				

			</div>



		</div><!-- /.modal-dialog -->
	</div><!-- /.modal -->



<div class="modal fade email-an-article-modal" tabindex="-1" role="dialog" aria-hidden="true" id="email-an-article-modal">
	<div class="modal-dialog" role="document">
		<div class="modal-content">
			<div class="modal-header">
				<h3 class="">Email an article</h3>
				<button type="button" class="close" data-dismiss="modal"></button>
			</div>
			<div class="modal-body">
				<p>You have chosen to share the following article:</p>
				<p><b id="email-an-article-title">How elderberries can help you fight the flu</b></p>
				<p>To proceed, simply complete the form below, and a link to the article will be sent by email on your behalf.<br>
					<b>Note:</b> Please don't include any URLs in your comments, as they will be removed upon submission.</p>
				<p>We do not store details you enter into this form. Please see our <a href="/privacy-policy" title="Read our Privacy Policy" target="_blank">privacy policy</a> for more information.</p>

				<form id="email-an-article-form">
					<fieldset class="form-container">
						<div>
							<label><em>*</em>Your Name (max. 30 chars)</label>
							<input id="fromName" type="text" name="fromName" maxlength="30" value="" required>
							<label for="fromName" generated="true" class="formError" style="display: none">The field 'Your Name' is required.</label>
						</div>
						<div>
							<label><em>*</em>Email Address</label>
							<input id="fromEmailAddress" class="formEmail" type="email" name="fromEmailAddress" maxlength="100" value="" required>
							<label for="fromEmailAddress" generated="true" class="formError" style="display: none">This is not a valid email address.</label>
						</div>
						<div>
							<label><em>*</em>Friend's Name (max. 30 chars)</label>
							<input id="toName" type="text" name="toName" maxlength="30" value="" required>
							<label for="toName" generated="true" class="formError" style="display: none">The field 'Friend's Name' is required.</label>
						</div>
						<div>
							<label><em>*</em>Friend's Email Address</label>
							<input id="toEmailAddress" type="email" name="toEmailAddress" maxlength="100" value="" required>
							<label for="toEmailAddress" generated="true" class="formError" style="display: none">The field 'Friend's Email Address' is required.</label>
						</div>

					</fieldset>


					<div id="email-an-article-reCAPTCHA" class="g-recaptcha" data-sitekey="6Le68KEUAAAAAOKVyWLvP5U0Dl2HT9dqR0J1hx7z"></div>




					<div class="buttonrow">
						<button type="submit" id="email_submit" class="btn-form form-submit secure">Send securely</button>
						<span class="form_secure_icon"></span>
					</div>

				</form>

				<div class="robots-nocontent">
					<div id="email-an-article-success" class="information"  style="display: none">
						<h2 class="message_box">Message sent successfully</h2>
						<p><b>The details of this article have been emailed on your behalf.</b></p>
						<p><a href="/" title="Click here to return to the MNT homepage">Click here</a> to return to the Medical News Today home page.</p>
					</div>
				</div>
			</div>
		</div>
	</div><!-- /.modal-dialog -->
</div>










<hr class="css_h1ksn" >






<div class="container"> 

<div class="row site_header"> 

<article  >

			<div class="col-xs-12 col-sm-12 col-md-12 col-lg-12 article_header"> 		<!-- Leaderboard BANNER advert -->

<div id="dlb1_container" class="mnt css_c4zij" >


<!-- header_ad code -->
<div class="mnt_history" style="display:none;">

	<a href="/whitelist-mnt"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_history_leaderboard.png" alt="Thank you for supporting Medical News Today"/></a>


</div>
    <div id='dlb1_unit' adonis-marker>
	<script type='text/javascript'>
		googleAdSlotInfo.push({
			"slotName":'DLB1',
			"slotContainer":'dlb1_container'		});
	</script>
	</div>
	<span class='bt-uid-tg' data-uid='5b84646203-160' style='display: none !important' data-style='width: 728px;height: 90px;background: rgba(255, 255, 255, 0.5);border: 2px solid #888;box-sizing: border-box;margin: 0 auto 0;'></span>

</div>






<!-- /header_ad code -->
<h1 itemprop="headline">Gleevec (imatinib)</h1>

</div> 	<div class="col-xs-12 col-sm-12 col-md-8 col-lg-8 main_content"> 	<div id="article_date">
			<span class="date_reviewed screen_only">Last reviewed		<time itemprop="lastReviewed" datetime="2019-06-09">
		Sun  9 June 2019		</time></span>
		
		<span class="date_reviewed mobile_only">Last reviewed		Sun  9 Jun 2019</span>
		
			</div>
		<div class="author_top">
	<span class='author_byline'>By Lindsay Slowiczek, PharmD</span>	</div>
				<div class="reviewer_top">
			<span class='reviewer_byline'>Reviewed by <a href='/reviewers' class='article_author' rel='author' title='MNT medical review team' >Catherine C. Peng, PharmD, BCPS</a></span>			</div>
			<span class="clearfix"></span>

<div class="article_body">
	<div itemprop="articleBody">
	<div class="article_toc collapsed article_collapsed">
<a class="collapsed__click" href="#"><i class="collapsed__icon"></i>Table of contents</a><ol class="collapsed__tabs hide">
<li><a href="#generic">Generic</a></li>








<li><a href="#side-effects">Side effects</a></li>








<li><a href="#gleevec-for-cml">Gleevec for CML</a></li>








<li><a href="#other-uses">Other uses</a></li>








<li><a href="#cost">Cost</a></li>








<li><a href="#dosage">Dosage</a></li>








<li><a href="#alternatives">Alternatives</a></li>








<li><a href="#gleevec-vs-tasigna">Gleevec vs. Tasigna</a></li>








<li><a href="#gleevec-vs-sprycel">Gleevec vs. Sprycel</a></li>








<li><a href="#gleevec-and-alcohol">Gleevec and alcohol</a></li>








<li><a href="#interactions">Interactions</a></li>








<li><a href="#how-to-take">How to take</a></li>








<li><a href="#how-it-works">How it works</a></li>








<li><a href="#pregnancy">Pregnancy</a></li>








<li><a href="#breastfeeding">Breastfeeding</a></li>








<li><a href="#overdose">Overdose</a></li>








<li><a href="#faqs">FAQs</a></li>








<li><a href="#expiration">Expiration</a></li>








<li><a href="#for-professionals">For professionals</a></li>








</ol>
</div>








<h2>What is Gleevec?</h2>








<p>Gleevec is a brand-name prescription medication. It's used to treat certain types of blood <a href="/info/cancer-oncology/" title="What is Cancer?" class="keywords">cancers</a> in adults and children. Gleevec is also used to treat a type of <a href="/articles/154322.php" title="What you should know about melanoma" class="keywords">skin cancer</a> and a type of gastrointestinal cancer.</p>








<p>Gleevec contains the drug imatinib mesylate, which belongs to a class of drugs called tyrosine kinase inhibitors.</p>








<p>Gleevec comes as a tablet that you take by mouth. You take the drug either once or twice a day, depending on the dosage your doctor prescribes.</p>








<h3>What it does</h3>








<p>The Food and Drug Administration (FDA) has approved Gleevec to treat certain types of blood cancers, including:</p>








<ul>
<li>Philadelphia chromosome-positive (Ph+) chronic myeloid <a href="/articles/142595.php" title="Leukemia: What you need to know" class="keywords">leukemia</a> (CML) in adults and children</li>








<li>Ph+ <a href="/articles/215500.php" title="Acute lymphoblastic leukemia: Causes and treatments" class="keywords">acute lymphocytic leukemia</a> (ALL) that's relapsed* or refractory* in adults</li>








<li>newly diagnosed Ph+ ALL in children</li>








<li>myelodysplastic/myeloproliferative diseases (<a href="/articles/285666.php" title="All you need to know about bone marrow" class="keywords">bone marrow</a> cancers) in adults with platelet-derived growth factor receptor (PDGFR) gene rearrangements</li>








<li>hypereosinophilic syndrome or chronic eosinophilic leukemia in adults</li>








<li>aggressive systemic mastocytosis in adults without the D816v c-Kit mutation</li>








</ul>
<p><em>* Relapsed cancer has returned after remission, which is a decrease in cancer signs and symptoms. Refractory cancer hasn't responded to previous cancer treatments.</em></p>








<p>Gleevec is also approved to treat:</p>








<ul>
<li>a type of skin cancer called dermatofibrosarcoma protuberans (DFSP) in adults</li>








<li>a type of gastrointestinal cancer called Kit-positive gastrointestinal stromal tumors (GIST) in adults</li>








</ul>
<p>For details, see the sections for "Gleevec for CML" and "Other uses for Gleevec."</p>








<h3>Gleevec effectiveness</h3>








<p>Gleevec has been found effective in treating several different types of blood cancers.</p>








<p>In one <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical study</a>, adults with newly diagnosed CML in the chronic phase took Gleevec for seven years. In this group, 96.6 % of people had a complete response to the drug. This means that no cancerous cells were found in their blood, and they had no symptoms of cancer.</p>








<p>Complete response is one way to describe the success rate. In the group of people who received standard <a href="/articles/158401.php" title="What you need to know about chemotherapy" class="keywords">chemotherapy</a>, 56.6% had a complete response.</p>








<p>Gleevec has also been found effective in treating gastrointestinal stromal tumors (GIST) in <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>. The overall survival rate was about four years. This means that half the people in the study lived for about four years after they started taking Gleevec. People who took Gleevec after having surgery lived for about five years after starting the drug.</p>








<p>To learn how effective Gleevec is in treating other types of cancers, see the "Other uses for Gleevec" section.</p>








<span class="anchor" id="generic"></span>
<h2>Gleevec generic</h2>








<p>Gleevec is available as a brand-name medication and as a generic form.</p>








<p>Gleevec contains the active drug ingredient imatinib mesylate.</p>








<span class="anchor" id="side-effects"></span>
<h2>Gleevec side effects</h2>








<p>Gleevec can cause mild or serious side effects. The following lists contain some of the key side effects that may occur while taking Gleevec. These lists don't include all possible side effects.</p>








<p>For more information on the possible side effects of Gleevec, talk with your doctor or pharmacist. They can give you tips on how to deal with any side effects that may be bothersome.</p>








<h3>More common side effects</h3>








<p>The more common side effects of Gleevec can include:</p>








<ul>
<li><a href="/articles/158634.php" title="What you should know about diarrhea" class="keywords">diarrhea</a></li>








<li>belly pain</li>








<li>
<a href="/articles/248002.php" title="Fatigue: Why am I so tired and what can I do about it?" class="keywords">fatigue</a> (lack of energy)</li>








<li>
<a href="/articles/159111.php" title="Everything you need to know about edema" class="keywords">edema</a> (swelling, typically in your legs, ankles, or feet and around your eyes)</li>








<li>muscle cramps or pain</li>








<li>nausea</li>








<li>vomiting</li>








<li>rash</li>








</ul>
<p>Many of these side effects may go away within a few days or a couple of weeks. If they're more severe or don't go away, talk with your doctor or pharmacist.</p>








<h3>Serious side effects</h3>








<p>Serious side effects from Gleevec aren't common, but they can occur. Call your doctor right away if you have serious side effects. Call 911 if your symptoms feel life-threatening or if you think you're having a medical emergency.</p>








<p>Serious side effects and their symptoms can include the following:</p>








<ul>
<li>Severe <a href="/articles/187978.php" title="What to know about water retention" class="keywords">fluid retention</a> (too much fluid or water) in and around your heart, lungs (pleural effusion), and belly (ascites). Symptoms can include:</li>








<ul>
<li>unexpected, rapid weight gain</li>








<li>chest pain</li>








<li>shortness of breath</li>








<li>trouble taking deep breaths</li>








<li>trouble breathing when you lie down</li>








<li>dry cough</li>








<li>swollen belly</li>








</ul>
<li>Blood disorders, including <a href="/articles/158800.php" title="Everything you need to know about anemia" class="keywords">anemia</a> (low levels of red blood cells), neutropenia (low levels of white blood cells), and thrombocytopenia (low levels of platelets). Symptoms can include:</li>








<ul>
<li>fatigue (lack of energy)</li>








<li>rapid heart rate</li>








<li>shortness of breath</li>








<li>frequent infections</li>








<li><a href="/articles/168266.php" title="Fever: What you need to know" class="keywords">fevers</a></li>








<li>bruising easily</li>








<li>bleeding gums</li>








<li>blood in urine or stool</li>








</ul>
<li>Congestive <a href="/articles/156849.php" title="Congestive heart failure: What you need to know" class="keywords">heart failure</a> and other heart problems, such as left-sided heart failure. Symptoms can include:</li>








<ul>
<li>unexpected weight gain</li>








<li>edema (swelling of your feet, ankles, and legs)</li>








<li>abnormal heart rate or rhythm (heartbeat that's too fast, too slow, or irregular)</li>








<li>chest pain</li>








<li>shortness of breath</li>








</ul>
<li>Liver damage or liver failure. Symptoms can include:</li>








<ul>
<li>nausea</li>








<li>diarrhea</li>








<li>loss of appetite</li>








<li>itchy skin</li>








<li>
<a href="/articles/165749.php" title="Everything you need to know about jaundice" class="keywords">jaundice</a> (yellowish color of your skin and the whites of your eyes)</li>








<li>edema (swelling of your legs, ankles, and feet)</li>








<li>ascites (fluid buildup in your belly)</li>








<li>frequent bruising</li>








<li>frequent bleeding</li>








</ul>
<li>Severe hemorrhage (bleeding that doesn't stop), most often in your intestines. Symptoms can include:</li>








<ul>
<li>blood in stool</li>








<li>black or tarry stool</li>








<li>fatigue (lack of energy)</li>








<li>coughing up blood</li>








<li>coughing up black sludge</li>








<li>nausea</li>








<li>stomach cramps</li>








</ul>
<li>Gastrointestinal problems, including perforations (tears) in your stomach or intestines. Symptoms can include:</li>








<ul>
<li>nausea</li>








<li>vomiting</li>








<li>severe pain in your stomach</li>








<li>fever</li>








<li>shortness of breath</li>








<li>fast heartbeat</li>








</ul>
<li>Severe skin problems. Symptoms can include:</li>








<ul>
<li>
<a href="https://www.medicalnewstoday.com/articles/323801.php" target="_blank" rel="noopener">erythema multiforme</a> (red patches or blisters, often on the soles of your feet or the palms of your hands)</li>








<li>Stevens-Johnson syndrome (fever; painful sores on your mouth, throat, eyes, genitals, or entire body)</li>








<li>fever</li>








<li>body aches</li>








</ul>
<li>
<a href="/articles/163729.php" title="What is hypothyroidism?" class="keywords">Hypothyroidism</a> (low thyroid levels) in people who have had their thyroid removed and are taking thyroid replacement medication. Symptoms can include:</li>








<ul>
<li>fatigue (lack of energy)</li>








<li><a href="/articles/150322.php" title="What to know about constipation" class="keywords">constipation</a></li>








<li><a href="/kc/depression-causes-symptoms-treatments-8933" title="What is depression and what can I do about it?" class="keywords">depression</a></li>








<li>feeling cold</li>








<li>dry skin</li>








<li>weight gain</li>








<li>memory problems</li>








</ul>
<li>Slowed growth in children. Symptoms can include:</li>








<ul>
<li>not growing at a normal rate</li>








<li>smaller size than other children their age</li>








</ul>
<li>
<a href="/articles/249141.php" title="What are the different types of tumors?" class="keywords">Tumor</a> lysis syndrome (when cancer cells release harmful chemicals into your blood). Symptoms can include:</li>








<ul>
<li>fatigue (lack of energy)</li>








<li>nausea</li>








<li>vomiting</li>








<li>diarrhea</li>








<li>muscle cramps</li>








<li>abnormal heart rhythm (heartbeat that's too fast, too slow, or irregular)</li>








<li>seizures</li>








</ul>
<li>Kidney damage. Symptoms can include:</li>








<ul>
<li>urinating less often than usual</li>








<li>edema (swelling of your legs, ankles, and feet)</li>








<li>fatigue (lack of energy)</li>








<li>nausea</li>








<li>confusion</li>








<li><a href="/articles/159283.php" title="What to know about high blood pressure" class="keywords">high blood pressure</a></li>








</ul>
<li>Side effects that can lead to motor vehicle accidents. Symptoms can include:</li>








<ul>
<li>dizziness</li>








<li>sleepiness</li>








<li>blurred vision</li>








</ul>
</ul>
<h3>Side effect details</h3>








<p>You may wonder how often certain side effects occur with this drug, or whether certain side effects pertain to it. Here's some detail on several of the side effects this drug may or may not cause.</p>








<p><strong>Allergic reaction</strong></p>








<p>As with most drugs, some people can have an allergic reaction after taking Gleevec. Symptoms of a mild allergic reaction can include:</p>








<ul>
<li>skin rash</li>








<li>itchiness</li>








<li>flushing (warmth and redness in your skin)</li>








</ul>
<p>A more severe allergic reaction is rare but possible. Symptoms of a severe allergic reaction can include:</p>








<ul>
<li>
<a href="/articles/216095.php" title="Everything you need to know about angioedema" class="keywords">angioedema</a> (swelling under your skin, typically in your eyelids, lips, hands, or feet)</li>








<li>swelling of your tongue, mouth, or throat</li>








<li>trouble breathing</li>








</ul>
<p>Call your doctor right away if you have a severe allergic reaction to Gleevec. Call 911 if your symptoms feel life-threatening or if you think you're having a medical emergency.</p>








<p><strong>Long-term side effects</strong></p>








<p>Some of the side effects seen in clinical studies can happen with long-term use of Gleevec. These include heart problems, such as congestive heart failure and left-sided heart failure.</p>








<p>In a <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1609324" target="_blank" rel="noopener">clinical study</a>, more than 500 people who took Gleevec for chronic myeloid leukemia (CML) were followed for up to 11 years. People in this long-term study had many of the same common side effects that were reported in shorter studies. However, these side effects seemed to improve over time.</p>








<p>Serious side effects seen with long-term use included:</p>








<ul>
<li>severe blood disorders (low levels of red blood cells, white blood cells, or platelets) in six people</li>








<li>heart problems, including congestive heart failure, in seven people</li>








<li>six cases of new cancer, including <a href="/articles/161727.php" title="What's to know about multiple myeloma?" class="keywords">multiple myeloma</a> in one person and <a href="/articles/150496.php" title="Everything you need to know about colon cancer" class="keywords">colon cancer</a> in another person</li>








</ul>
<p>Side effects were most common during the first year of treatment with Gleevec. But the longer that people took Gleevec, the less often they had many of these side effects. For example, in the first year of the study, three people had serious blood disorders, but after the fifth year, only one person did.</p>








<p>In a <a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2711891" target="_blank" rel="noopener">five-year study</a> of people with gastrointestinal stromal tumors (GIST), 16% of people stopped taking Gleevec because of side effects. The side effects were similar to those described in the CML study above. Forty percent of people in the study were prescribed lower doses of the drug to ease their side effects.</p>








<p>If you're concerned about possible long-term side effects of Gleevec, talk with your doctor. They can suggest ways to reduce your risks for certain side effects.</p>








<p><strong>Eye-related side effects</strong></p>








<p>In <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a> of Gleevec, some people had eye-related side effects such as swelling and blurry vision.</p>








<p>Eyelid swelling and swelling around the eyes were some of the most common side effects. Up to 74.2% of people who took Gleevec had periorbital edema (swelling of the eye area).</p>








<p>If you have this side effect, your doctor may prescribe a diuretic (often called a water pill). Diuretics help your body get rid of extra water and salt when you urinate. This eases fluid buildup. Your doctor may also lower your dose of Gleevec, if needed.</p>








<p>In addition, <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a> reported that up to 11.1% of people who took Gleevec had blurry vision. If you have blurry vision, don't drive or use heavy machinery. And be sure to tell your doctor that you can't see clearly.</p>








<p>Other less common eye-related side effects included:</p>








<ul>
<li>dry eye</li>








<li>watery eyes</li>








<li>eye irritation</li>








<li>
<a href="/articles/157671.php" title="What is infective conjunctivitis, or pink eye?" class="keywords">conjunctivitis</a> (often called pink eye)</li>








<li>broken blood vessels in the eye</li>








<li>swelling of the retina (a layer of tissue in the back of your eye)</li>








</ul>
<p>If you're taking Gleevec and have any eye-related side effects, talk with your doctor. They can suggest ways to ease your symptoms.</p>








<p><strong>Hair loss</strong></p>








<p><a href="/articles/70956.php" title="What's to know about alopecia areata?" class="keywords">Hair loss</a> (alopecia) is a possible side effect of taking Gleevec.</p>








<p>One <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">study</a> tested how Gleevec works in people with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). Seven percent of these people had hair loss after they took the drug.</p>








<p>In another <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">study</a>, people took Gleevec to treat gastrointestinal stromal tumors (GIST). Between 11.9% and 14.8% of these people had hair loss. This side effect was seen more often in people who took higher doses of Gleevec.</p>








<p>Hair loss due to cancer treatment is usually temporary. If you're concerned about this side effect, talk with your doctor. They can suggest tips to help you reduce hair loss during your treatment.</p>








<p><strong>Rash and other skin side effects</strong></p>








<p>Gleevec can cause mild and more serious side effects to your skin.</p>








<p><em><strong>More common skin reactions</strong></em></p>








<p>Rashes and other mild skin reactions are very common in people who take Gleevec.</p>








<p>In <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>, people took Gleevec to treat Ph+ chronic myeloid leukemia (CML). Up to 40.1% of these people had rashes or other skin reactions after taking the drug.</p>








<p>In other <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>, people took Gleevec for gastrointestinal stromal tumors (GIST). After taking the drug, up to 49.8% of these people had rashes or other skin reactions. These included:</p>








<ul>
<li>peeling of the skin</li>








<li>dry skin</li>








<li>skin discoloration (a bluish tint to the skin)</li>








<li>infections of hair follicles (sacs under your skin that hold the roots of your hair)</li>








<li>erythema (reddening of skin)</li>








<li>purpura (purple-colored spots on skin)</li>








</ul>
<p>These side effects were more common in people who took higher doses of Gleevec.</p>








<p>If you're concerned about rashes or other mild skin reactions due to Gleevec, talk with your doctor. They can suggest ways to help ease your symptoms.</p>








<p><em><strong>Serious skin reactions</strong></em></p>








<p>In <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>, serious skin reactions were very rare in people who took Gleevec. Up to 1% of people who took this drug had a serious skin reaction. Examples of serious drug-related skin effects include:</p>








<ul>
<li>Stevens-Johnson syndrome (fever; painful sores on your mouth, throat, eyes, genitals, or entire body)</li>








<li>exfoliative dermatitis (skin peeling over large parts of your body)</li>








<li>vesicular rash (small blisters and a rash)</li>








</ul>
<p>Rashes and blisters can be very painful. And if they're not treated, they can trap bacteria and lead to serious infections. So if you're taking Gleevec and have a rash or blisters with a fever or you don't feel well, tell your doctor right away. Also mention any other skin reactions you have.</p>








<p><strong>Side effects affecting driving</strong></p>








<p>In <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>, some people who took Gleevec had side effects that could affect their ability to drive. These included:</p>








<ul>
<li>dizziness: in up to 19.4% of people</li>








<li>blurry vision: in up to 11.1% of people</li>








<li>fatigue: in 74.9% of people</li>








</ul>
<p>These side effects may affect your ability to drive or use heavy machinery. There have been reports of motor vehicle accidents by people who took Gleevec. So you should use caution when driving or using machinery while taking Gleevec.</p>








<p><strong>Slowed wound healing </strong>(not a side effect)</p>








<p>Slowed wound healing wasn't reported in <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a> of Gleevec.</p>








<p>Some types of cancer treatment, such as radiation and chemotherapy, may weaken your immune system. This can make wounds heal more slowly.</p>








<p>If you're concerned about slowed wound healing, ask your doctor whether you have a higher risk for this problem based on your medical condition.</p>








<p><strong>Liver cancer</strong> (may not be a side effect)</p>








<p><a href="/articles/172408.php" title="Everything you need to know about liver cancer" class="keywords">Liver cancer</a> wasn't reported as a side effect in clinical studies of Gleevec. However, liver damage has occurred in both short- and long-term use of Gleevec. Some cases of liver damage have led to liver failure and liver transplant.</p>








<p>Liver damage is often found when doctors monitor enzymes (special proteins) that are made in the liver. Enzyme levels that are higher than normal can be a sign of liver damage.</p>








<p>Some physical symptoms of liver damage include:</p>








<ul>
<li>nausea</li>








<li>diarrhea</li>








<li>loss of appetite</li>








<li>itchy skin</li>








<li>jaundice (yellowish color of your skin and the whites of the eyes)</li>








<li>edema (swelling of your legs, ankles, and feet)</li>








<li>ascites (fluid buildup in your belly)</li>








<li>frequent bruising</li>








<li>frequent bleeding</li>








</ul>
<p>During <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>, up to 5% of people with chronic myeloid leukemia (CML) had severely high liver enzyme levels during Gleevec treatment. Up to 6.8% of people with gastrointestinal stromal tumors (GIST) had severely high liver enzyme levels during treatment. And up to 0.1% of people who took Gleevec had liver failure.</p>








<p>While you take Gleevec, your doctor will monitor how your liver is working. If you have signs of liver damage while taking Gleevec, your doctor may reduce your dose. This may prevent damage that could lead to liver failure.</p>








<h3>Side effects in children</h3>








<p>Children in clinical studies who took Gleevec had side effects that were very similar to those in adults. But researchers found these exceptions:</p>








<ul>
<li>fewer children had muscle or bone pain than adults had</li>








<li>edema (swelling of the legs, ankles, feet, and area around the eyes) wasn't reported in children</li>








</ul>
<p>The most commonly reported side effects reported in children were nausea and vomiting. The most common serious side effects were low levels of white blood cells and platelets.</p>








<p>If your child has these side effects, talk with your child's doctor about ways to manage them.</p>








<span class="anchor" id="gleevec-for-cml"></span>
<!--[MMR]--><!--[END MMR]--><h2>Gleevec for CML</h2>








<p>The Food and Drug Administration (FDA) has approved Gleevec for certain people with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). The Philadelphia chromosome is chromosome number 22 with a defect. People with Ph+ CML have a specific change in their DNA that causes too many white blood cells to form.</p>








<p>CML is divided into three phases:</p>








<ul>
<li>
<strong>Chronic phase.</strong> This is the first phase of CML. Most people are diagnosed with CML during the chronic phase. Symptoms are usually mild, if there are any at all.</li>








<li>
<strong>Accelerated phase.</strong> In this second phase, the number of cancer cells in your blood increases. You may have more symptoms, such as fever and weight loss.</li>








<li>
<strong>Blast crisis phase.</strong> In this most advanced phase, cancer cells in your blood have spread to other organs and tissues. Your symptoms may be more severe.</li>








</ul>
<div id="onequarter-of-article"></div>
<p>Gleevec is approved to treat newly diagnosed Ph+ CML in the chronic phase in people of all ages.</p>








<p>It's also approved to treat Ph+ CML in the chronic, accelerated, or blast crisis phase for people who have had unsuccessful treatment with interferon-alpha therapy. Interferon-alpha is a drug that was used more often in the past to treat CML. It's been replaced by drugs such as Gleevec that have been shown to be more effective.</p>








<h3>Effectiveness</h3>








<p>In a seven-year <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical study</a>, the survival rate for adults who took Gleevec for newly diagnosed Ph+ CML was 86.4%. This means that 86.4% of the adults survived for seven years after they started taking Gleevec. This was compared to 83.3% of people who took standard chemotherapy drugs.</p>








<p>In a <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical study,</a> people who had previously tried interferon-alpha for CML took Gleevec. Some of these people had a complete response to Gleevec treatment. This means that no cancerous cells were found in their blood, and they had no symptoms of cancer. Here's how many people with CML had a complete response to taking Gleevec:</p>








<ul>
<li>95% of people in the chronic phase</li>








<li>38% of people in the accelerated phase</li>








<li>7% of people in the blast crisis phase</li>








</ul>
<p>The clinical study also included children with Ph+ CML in the chronic phase. In the group that took Gleevec, 78% of children had a complete response to the drug.</p>








<span class="anchor" id="other-uses"></span>
<!--[DLB]--><!-- Leaderboard BANNER advert -->

<div id="dlb2_container" class="mnt css_c4zij" >


<!-- header_ad code -->
<div class="mnt_history" style="display:none;">

	<a href="/whitelist-mnt"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_history_leaderboard.png" alt="Thank you for supporting Medical News Today"/></a>


</div>
    <div id='dlb2_unit' adonis-marker>
	<script type='text/javascript'>
		googleAdSlotInfo.push({
			"slotName":'DLB2',
			"slotContainer":'dlb2_container'		});
	</script>
	</div>
	<span class='bt-uid-tg' data-uid='5b846471dd-160' style='display: none !important' ></span>

</div>






<!-- /header_ad code --><!--[END DLB]--><h2>Other uses for Gleevec</h2>








<p>In addition chronic myeloid leukemia (see above), the Food and Drug Administration (FDA) has approved Gleevec to treat several other conditions.</p>








<h3>Gleevec for acute lymphocytic leukemia (ALL)</h3>








<p>Gleevec is FDA-approved to treat:</p>








<ul>
<li>Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) that's relapsed* or refractory* in adults</li>








<li>newly diagnosed Ph+ ALL in children when used with chemotherapy</li>








</ul>
<p><em>* Relapsed cancer has returned after remission, which is a decrease in cancer signs and symptoms. Refractory cancer hasn't responded to previous cancer treatments.</em></p>








<p>In a <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical study</a>, 19% of adults with relapsed or refractory ALL who took Gleevec had a complete response in their blood to treatment. This means that they had no symptoms of cancer.</p>








<p>A clinical study also looked at children with ALL who took Gleevec and had chemotherapy. For 70% of the children, their cancer didn't get worse for four years.</p>








<h3>Gleevec for other types of blood cancers</h3>








<p>Gleevec is FDA-approved to treat other types of blood cancers, including:</p>








<ul>
<li>
<strong>Myelodysplastic/myeloproliferative diseases (bone marrow cancers) in adults with platelet-derived growth factor receptor (PDGFR) gene rearrangements.</strong> In a small <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical study</a>, 45% of people treated with Gleevec had a complete response in their blood to treatment. This means that no cancer cells were found in their blood, and they had no symptoms of cancer.</li>








<li>
<strong>Hypereosinophilic syndrome and/or chronic eosinophilic leukemia in adults, including people with FIP1L1-PDGFRα fusion kinase.</strong> In small <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>, 100% of people with the PDGFR gene mutation who took Gleevec had a complete response in their blood to treatment. Between 21% and 58% of people without the gene mutation or with an unknown mutation status who took Gleevec had a complete response in their blood.</li>








<li>
<strong>Aggressive systemic mastocytosis in adults without the D816v c-Kit mutation.</strong> In a small <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical study</a>, 100% of people with the FIP1L1-PDGFRα fusion kinase mutation who were treated with Gleevec had a complete response to treatment.</li>








</ul>
<h3>Gleevec for skin cancer</h3>








<p>Gleevec is FDA-approved to treat dermatofibrosarcoma protuberans, a rare type of skin cancer, in adults. It's approved for people whose cancer:</p>








<ul>
<li>can't be operated on</li>








<li>has come back after treatment</li>








<li>is metastatic (has spread to other parts of the body)</li>








</ul>
<p>A small number of people have been treated with Gleevec for this condition in <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>. Of those people who took Gleevec, 39% had a complete response to treatment. This means that a skin biopsy (removing and testing a small sample of skin) showed no signs of cancer.</p>








<h3>Gleevec for gastrointestinal cancer</h3>








<p>Gleevec is FDA-approved to treat Kit-positive gastrointestinal stromal tumors (GIST) in adults that can't be operated on or are metastatic (have spread to other parts of the body). Gleevec is also approved to treat GIST in adults who have had surgery to remove tumors. This form of treatment (adjuvant treatment) is used to prevent the cancer from returning after surgery.</p>








<p>In <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">clinical studies</a>, people with GIST that couldn't be surgically removed took 400 or 800 mg of Gleevec. They survived for about four years.</p>








<p>Other people with GIST did have surgery. Between 14 and 70 days later, they started taking Gleevec in the study. They had about a 60% lower risk of either dying or having the cancer return over a period of 12 months. This was compared to people who took a <a href="/articles/306437.php" title="Placebos: The power of the placebo effect" class="keywords">placebo</a> (treatment with no active medication).</p>








<h3>Off-label uses for Gleevec</h3>








<p>In addition to the uses listed above, Gleevec may be used off-label for other uses. <a href="https://www.healthline.com/health/general-use/off-label-drug-use" target="_blank" rel="noopener">Off-label drug use</a> is when a drug that's approved for one use is prescribed for a different one that's not approved.</p>








<p>Gleevec may be used off-label for other cancers, including:</p>








<ul>
<li>
<a href="/articles/150086.php" title="Prostate cancer in detail" class="keywords">prostate cancer</a>, according to a <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449347/" target="_blank" rel="noopener">2015 study</a>
</li>








<li>
<a href="/articles/154322.php" title="What you should know about melanoma" class="keywords">melanoma</a>, according to <a href="https://www.nccn.org/patients/guidelines/melanoma/index.html" target="_blank" rel="noopener">National Comprehensive Cancer Network</a> treatment guidelines</li>








<li>
<a href="/info/diabetes/type1diabetes.php" title="What is type 1 diabetes?" class="keywords">type 1 diabetes</a>, according to a <a href="https://clinicaltrials.gov/ct2/show/study/NCT01781975" target="_blank" rel="noopener">2018 clinical trial</a>
</li>








</ul>
<p>However, there isn't much research on how Gleevec works in humans with these conditions. More studies are needed to determine whether Gleevec helps treat each condition.</p>








<h3>Gleevec for children</h3>








<p>Gleevec is FDA-approved as a treatment for children with the following conditions:</p>








<ul>
<li>newly diagnosed Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase (the first phase of the disease)</li>








<li>newly diagnosed Ph+ acute lymphocytic leukemia (ALL) when used with chemotherapy</li>








</ul>
<p>Gleevec is approved for use in children of all ages. However, there haven't been studies on how safe or effective Gleevec is in children younger than age 1 year.</p>








<span class="anchor" id="cost"></span>
<h2>Gleevec cost</h2>








<p>As with all medications, the cost of Gleevec can vary. To find current prices for Gleevec in your area, check out <a href="GoodRx.com" target="_blank" rel="noopener">GoodRx.com</a>:</p>








<div id="goodrx_fair-price_widget"></div>








<script>var _grxdn = "gleevec";(function(d,t){var g=d.createElement(t),s=d.getElementsByTagName(t)[0];g.src="//s3.amazonaws.com/assets.goodrx.com/static/widgets/fair.min.js";s.parentNode.insertBefore(g,s)}(document,"script"));</script><p>The cost you find on <a href="GoodRx.com" target="_blank" rel="noopener">GoodRx.com</a> is what you may pay without insurance. The actual price you'll pay depends on your insurance coverage and the pharmacy you use.</p>








<h3>Financial and insurance assistance</h3>








<p>If you need financial support to pay for Gleevec , or if you need help understanding your insurance coverage, help is available.</p>








<p>Novartis Pharmaceutical Corporation, the manufacturer of Gleevec, offers a program called Novartis Oncology Universal Co-pay Program. For more information and to find out if you're eligible for support, call 877-577-7756 or visit the <a href="https://www.copay.novartisoncology.com/?name=gleevec" target="_blank" rel="noopener">program website</a>.</p>








<span class="anchor" id="dosage"></span>
<h2>Gleevec dosage</h2>








<p>The Gleevec dosage your doctor prescribes will depend on several factors. These include:</p>








<ul>
<li>the type and severity of the condition you're using Gleevec to treat</li>








<li>age</li>








<li>weight (for children)</li>








<li>presence of gene mutations</li>








<li>other medical conditions you may have</li>








<li>other medication you may take</li>








<li>side effects you may have</li>








</ul>
<p>The dose you will receive depends on your cancer. For some cancers, your doctor may start you on a low dosage. Then they'll adjust it over time to reach the dosage that's right for you.</p>








<p>The following information describes dosages that are commonly used or recommended. <strong>However, be sure to take the dosage your doctor prescribes for you.</strong> Your doctor will determine the best dosage to suit your needs.</p>








<h3>Drug forms and strengths</h3>








<p>Gleevec comes as a tablet that you take by mouth (you swallow it). It's available in 100-mg tablets and 400-mg tablets.</p>








<p>The 100-mg and 400-mg tablets come in bottles. The 400-mg tablets also come in blister packs that are hard for children to open.</p>








<h3>Gleevec dosages</h3>








<p>The following doses are typical starting dosages for each condition:</p>








<ul>
<li>
<strong>adults with Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase (the first phase of the disease):</strong> 400 mg/day</li>








<li>
<strong>adults with Ph+ CML in the accelerated or blast crisis phase (the second and third phases of the disease):</strong> 600 mg/day</li>








<li>
<strong>adults with Ph+ acute lymphocytic leukemia (ALL):</strong> 600 mg/day</li>








<li>
<strong>adults with myelodysplastic/myeloproliferative disease:</strong> 400 mg/day</li>








<li>
<strong>adults with aggressive systemic mastocytosis:</strong> 100 mg or 400 mg/day</li>








<li>
<strong>adults with hypereosinophilic syndrome and/or chronic eosinophilic leukemia:</strong> 100 mg/day or 400 mg/day</li>








<li>
<strong>adults with dermatofibrosarcoma protuberans:</strong> 800 mg/day</li>








<li>
<strong>adults with gastrointestinal stromal tumors (GIST):</strong> 400 mg/day</li>








</ul>
<p>Your doctor may prescribe a different dosage for you. They'll base it on how well your body responds to the drug, how severe your side effects are, and other factors. If you have questions about the right dosage of Gleevec for you, talk with your doctor.</p>








<h3>Pediatric dosage</h3>








<p>Dosages for children are the following:</p>








<ul>
<li>
<strong>children with Ph+ CML in the chronic phase (the first phase of the disease):</strong> 340 mg/m2/day</li>








<li>
<strong>children with Ph+ ALL:</strong> 340 mg/m2/day to be taken with chemotherapy</li>








</ul>
<p>Your child's doctor will base the dosage on your child's height and weight. (So 340 mg/m2 means 340 mg per square meter of body surface area.) For example, if your child is 4 feet tall and weighs 49 lbs., their body surface area is about 0.87 m2. So the dosage for Ph+ CML would be 300 mg.</p>








<h3>What if I miss a dose?</h3>








<p>If you miss a dose of Gleevec, take one as soon as you remember. If it's almost time for your next dose, wait and take the next dose as scheduled. Don't take two doses to make up for the missed dose. This can increase your risk for serious side effects.</p>








<h3>Will I need to use this drug long term?</h3>








<p>Gleevec is meant to be used as a long-term treatment. If you and your doctor determine that Gleevec is safe and effective for you, you'll likely take it long term.</p>








<span class="anchor" id="alternatives"></span>
<!--[MMR]--><!--[END MMR]--><h2>Alternatives to Gleevec</h2>








<p>Other drugs are available that can treat your condition. Some may be better suited for you than others. If you're interested in finding an alternative to Gleevec, talk with your doctor to learn more about other medications that may work well for you.</p>








<p><strong>Note:</strong> Some of the drugs listed here are used off-label to treat these specific conditions.</p>








<h3>Alternatives for CML</h3>








<p>Examples of other drugs that may be used to treat Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) are:</p>








<ul>
<li>dasatinib (Sprycel)</li>








<li>nilotinib (Tasigna)</li>








<li>bosutinib (Bosulif)</li>








<li>ponatinib (Iclusig)</li>








<li>omacetaxine (Synribo)</li>








<li>daunorubicin (Cerubidine)</li>








<li>cytarabine</li>








<li>interferon-alpha (Intron A)</li>








</ul>
<h3>Alternatives for GIST</h3>








<p>Examples of other drugs that may be used to treat gastrointestinal stromal tumors (GIST) are:</p>








<ul>
<li>sunitinib (Sutent)</li>








<li>regorafenib (Stivarga)</li>








<li>sorafenib (Nexavar)</li>








<li>nilotinib (Tasigna)</li>








<li>dasatinib (Sprycel)</li>








<li>pazopanib (Votrient)</li>








</ul>
<p>Alternatives for other conditions Gleevec may treat are also available. Talk with your doctor about which medications can be used for your condition.</p>








<span class="anchor" id="gleevec-vs-tasigna"></span>
<h2>Gleevec vs. Tasigna</h2>








<p>You may wonder how Gleevec compares to other medications that are prescribed for similar uses. Here we look at how Gleevec and Tasigna are alike and different.</p>








<h3>Uses</h3>








<p>The Food and Drug Administration (FDA) has approved both Gleevec and Tasigna to treat certain types of blood cancers.</p>








<p>Both drugs are FDA-approved to treat newly diagnosed Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase in adults and children.</p>








<p>Chronic myeloid leukemia (CML) is divided into three phases:</p>








<ul>
<li>
<strong>Chronic phase.</strong> This is the first phase of CML. Most people are diagnosed with CML during the chronic phase. Symptoms are usually mild, if there are any at all.</li>








<li>
<strong>Accelerated phase.</strong> In this second phase, the number of cancer cells in your blood increases. You may have more symptoms, such as fever and weight loss.</li>








<li>
<strong>Blast crisis phase.</strong> In this most advanced phase, cancer cells in your blood have spread to other organs and tissues. Your symptoms may be more severe.</li>








</ul>
<p>Gleevec is approved to treat Philadelphia-positive (Ph+) CML in adults who are in the chronic, accelerated, or blast crisis phase if interferon-alpha therapy hasn't worked.</p>








<p>Interferon-alpha is a drug that was commonly used to treat CML in the past. It's a man-made drug that acts like certain immune system proteins and prevents the growth of cancer cells.</p>








<p>Tasigna is approved in to treat Ph+ CML in the chronic or accelerated phases in adults if other treatments haven't worked, including treatment with Gleevec. Tasigna isn't approved for the blast crisis phase.</p>








<p>Tasigna is also approved to treat Ph+ CML in children ages 1 year and older if other treatments haven't worked. Gleevec is approved to treat newly diagnosed Ph+ CML in children.</p>








<p>Gleevec is also approved to treat other types of cancers. See the "Other uses for Gleevec" section to learn more.</p>








<h3>Drug forms and administration</h3>








<p>Gleevec contains the drug imatinib. Tasigna contains the drug nilotinib.</p>








<p>Gleevec comes as a tablet. Tasigna comes as a capsule. Both drugs are taken by mouth.</p>








<p>Gleevec is taken once or twice a day, depending on your dose. Tasigna is taken twice a day.</p>








<p>Gleevec comes as 100-mg and 400-mg tablets. Tasigna comes as 50-mg, 150-mg, and 200-mg capsules.</p>








<h3>Side effects and risks</h3>








<p>Gleevec and Tasigna contain similar drugs. Therefore, both medications can cause very similar side effects. Below are examples of these side effects.</p>








<p><strong>More common side effects</strong></p>








<p>These lists contain examples of more common side effects that can occur with Gleevec, with Tasigna, or with both drugs (when taken individually).</p>








<ul>
<li><strong>Can occur with Gleevec:</strong></li>








<ul>
<li>edema (swelling of your legs, ankles, and feet, and around your eyes)</li>








<li>muscle cramps</li>








<li>muscle pain</li>








<li>bone pain</li>








<li>stomach pain</li>








</ul>
<li><strong>Can occur with Tasigna:</strong></li>








<ul>
<li><a href="/articles/73936.php" title="What is causing this headache?" class="keywords">headache</a></li>








<li>itchy skin</li>








<li>cough</li>








<li>constipation</li>








<li>joint pain</li>








<li>nasopharyngitis (common cold)</li>








<li>fever</li>








<li>night sweats</li>








</ul>
<li><strong>Can occur with both Gleevec and Tasigna:</strong></li>








<ul>
<li>nausea</li>








<li>vomiting</li>








<li>diarrhea</li>








<li>rash</li>








<li>fatigue (lack of energy)</li>








</ul>
</ul>
<p><strong>Serious side effects</strong></p>








<div id="middle-of-article"></div>
<p>These lists contain examples of serious side effects that can occur with Gleevec, with Tasigna, or with both drugs (when taken individually).</p>








<ul>
<li><strong>Can occur with Gleevec:</strong></li>








<ul>
<li>congestive heart failure or heart problems such as left-sided heart failure</li>








<li>gastrointestinal perforations (holes in your stomach or intestines)</li>








<li>severe skin reactions, including Stevens-Johnson syndrome (fever; painful sores on your mouth, throat, eyes, genitals, or entire body)</li>








<li>kidney damage</li>








<li>hypothyroidism (low thyroid levels) in people who have had their thyroid removed</li>








</ul>
<li><strong>Can occur with Tasigna:</strong></li>








<ul>
<li>long QT interval (abnormal electrical activity in your heart), which is rare but could lead to sudden death</li>








<li>blocked blood vessels in the heart</li>








<li><a href="/articles/160459.php" title="What's to know about chronic pancreatitis?" class="keywords">pancreatitis</a></li>








<li>electrolyte imbalances (high or low levels of certain minerals)</li>








</ul>
<li><strong>Can occur with both Gleevec and Tasigna:</strong></li>








<ul>
<li>blood disorders, including anemia (low levels of red blood cells), neutropenia (low levels of white blood cells), and thrombocytopenia (low levels of platelets)</li>








<li>liver damage</li>








<li>tumor lysis syndrome (cancer cells release harmful chemicals into your blood)</li>








<li>hemorrhage (bleeding that doesn't stop)</li>








<li>severe fluid retention (too much fluid or water)</li>








<li>slowed growth in children</li>








</ul>
</ul>
<h3>Effectiveness</h3>








<p>Gleevec and Tasigna have different FDA-approved uses. But they both treat Ph+ CML in the chronic and accelerated phases if certain other treatments haven't worked. CML has three phases: chronic (phase 1), accelerated (phase 2), and blast crisis (phase 3).</p>








<p>The use of Gleevec and Tasigna in treating newly diagnosed Ph+ CML in adults has been directly compared in a <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0912614" target="_blank" rel="noopener">clinical study</a>. Researchers compared people who took either 400 mg of Gleevec once a day or 300 mg of Tasigna twice a day.</p>








<p>After 12 months of treatment, 65% of people who took Gleevec had no Ph+ cells in their bone marrow (where cancerous CML cells grow). Of people who took Tasigna, 80% had no Ph+ cells in their bone marrow.</p>








<p>After five years of treatment, 60% of people who took Gleevec had a significantly reduced number of cancerous genes in their blood. This was compared to 77% of people who took Tasigna.</p>








<p>Also after five years of treatment, 91.7% of people who took Gleevec were still alive. That's compared to 93.7% of people who took Tasigna.</p>








<p>The results of this study suggest that Tasigna may be more effective than Gleevec at treating newly diagnosed Ph+ CML in the chronic phase.</p>








<h3>Costs</h3>








<p>Gleevec and Tasigna are both brand-name drugs. Tasigna doesn't have a generic form, but Gleevec has a generic form called imatinib. Brand-name medications usually cost more than generics.</p>








<p>According to estimates on <a href="GoodRx.com," target="_blank" rel="noopener">GoodRx.com,</a> brand-name Gleevec may cost less than Tasigna. The generic form of Gleevec (imatinib) also costs less than Tasigna. The actual price you'll pay for either drug depends on your dose, insurance plan, your location, and the pharmacy you use.</p>








<span class="anchor" id="gleevec-vs-sprycel"></span>
<!--[DLB]--><div id="hl-incontent-video-ad"></div>
<div id="div-gpt-ad-out-of-page"></div>
<script type="text/javascript">
	googleAdSlotInfo.push({
		"slotName":'out-of-page',
		"slotContainer":'div-gpt-ad-out-of-page'	});
</script><!--[END DLB]--><h2>Gleevec vs. Sprycel</h2>








<p>You may wonder how Gleevec compares to other medications that are prescribed for similar uses. Here we look at how Gleevec and Sprycel are alike and different.</p>








<h3>Uses</h3>








<p>The Food and Drug Administration (FDA) has approved both Gleevec and Sprycel to treat certain types of blood cancers.</p>








<p>Both drugs are both FDA-approved to treat newly diagnosed Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase in adults and children.</p>








<p>CML is divided into three phases:</p>








<ul>
<li>
<strong>Chronic phase.</strong> This is the first phase of CML. Most people are diagnosed with CML during the chronic phase. Symptoms are usually mild, if there are any at all.</li>








<li>
<strong>Accelerated phase.</strong> In this second phase, the number of cancer cells in your blood increases. You may have more symptoms, such as fever and weight loss.</li>








<li>
<strong>Blast crisis phase.</strong> In this most advanced phase, cancer cells in your blood have spread to other organs and tissues. Your symptoms may be more severe.</li>








</ul>
<p>Gleevec and Sprycel are used to treat Ph+ CML in adults in the chronic phase.</p>








<p>Gleevec is also used to treat Ph+ CML in adults in the chronic, accelerated, or blast-crisis phases if interferon-alpha therapy didn't work. Interferon-alpha is a drug that was commonly used to treat CML in the past. It's a man-made drug that acts like certain immune system proteins and prevents the growth of cancer cells.</p>








<p>Sprycel is also used to treat Ph+ CML in adults in the chronic, accelerated, or blast-crisis phases if Gleevec didn't work.</p>








<p>Both Gleevec and Sprycel are approved to treat Ph+ CML in the chronic phase in children. They are both also approved to treat Ph+ acute lymphocytic leukemia (ALL) in children along with chemotherapy.</p>








<p>Gleevec is also approved to treat other types of cancers. See the "Other uses for Gleevec" section to learn more.</p>








<h3>Drug forms and administration</h3>








<p>Gleevec contains the drug imatinib. Sprycel contains the drug dasatinib.</p>








<p>Gleevec and Sprycel both come as tablets that you take by mouth (you swallow them).</p>








<p>Gleevec tablets come in two strengths: 100 mg and 400 mg. It's taken once or twice a day, depending on your dose.</p>








<p>Sprycel tablets come in the following strengths: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. Sprycel is taken once a day.</p>








<h3>Side effects and risks</h3>








<p>Gleevec and Sprycel are similar but contain different drugs. Therefore, both medications can cause very similar side effects. Below are examples of these side effects.</p>








<p><strong>More common side effects</strong></p>








<p>These lists contain examples of more common side effects that can occur with Gleevec, with Sprycel, or with both drugs (when taken individually).</p>








<ul>
<li><strong>Can occur with Gleevec:</strong></li>








<ul>
<li>vomiting</li>








<li>muscle cramps</li>








<li>belly pain</li>








<li>eye-area edema (swelling around eyes)</li>








</ul>
<li><strong>Can occur with Sprycel:</strong></li>








<ul>
<li>trouble breathing</li>








<li>headache</li>








<li>bleeding</li>








<li>weakened immune system (your body can't fight infections as well)</li>








</ul>
<li><strong>Can occur with both Gleevec and Sprycel:</strong></li>








<ul>
<li>edema (swelling of your legs, ankles, and feet)</li>








<li>nausea</li>








<li>muscle pain</li>








<li>bone pain</li>








<li>diarrhea</li>








<li>rash</li>








<li>fatigue (lack of energy)</li>








</ul>
</ul>
<p><strong>Serious side effects</strong></p>








<p>These lists contain examples of serious side effects that can occur with Gleevec, with Sprycel, or with both drugs (when taken individually).</p>








<ul>
<li><strong>Can occur with Gleevec:</strong></li>








<ul>
<li>heart problems, such as congestive heart failure</li>








<li>liver damage</li>








<li>gastrointestinal perforations (holes in your stomach or intestines)</li>








<li>kidney damage</li>








<li>hypothyroidism (low thyroid levels) in people who have had their thyroid removed</li>








</ul>
<li><strong>Can occur with Sprycel:</strong></li>








<ul>
<li>pulmonary arterial <a href="/articles/150109.php" title="Everything you need to know about hypertension" class="keywords">hypertension</a> (high blood pressure in blood vessels in your lungs)</li>








<li>long QT interval (a type of abnormal electrical activity in your heart)</li>








<li>ischemic <a href="/articles/151444.php" title="How to spot and treat a heart attack" class="keywords">heart attack</a> (lack of oxygen to heart muscles)</li>








</ul>
<li><strong>Can occur with both Gleevec and Sprycel:</strong></li>








<ul>
<li>severe fluid retention (too much fluid or water) around your lungs, heart, and belly</li>








<li>severe blood disorders (low levels of red blood cells, platelets, or white blood cells)</li>








<li>severe hemorrhage (bleeding that doesn't stop)</li>








<li>severe skin reactions, including Stevens-Johnson syndrome (fever; painful sores on your mouth, throat, eyes, genitals, or entire body)</li>








<li>tumor lysis syndrome (cancer cells release harmful chemicals into your blood)</li>








<li>abnormal heart rate or rhythm (heartbeat that's too fast, too slow, or irregular)</li>








<li>stunted growth in children</li>








</ul>
</ul>
<h3>Effectiveness</h3>








<p>Gleevec and Sprycel have different FDA-approved uses. But they both treat newly diagnosed Ph+ CML in the chronic phase (the first phase of CML) in adults and children. Gleevec and Sprycel also both treat Ph+ ALL in children when used in combination with chemotherapy.</p>








<p>In addition, both Gleevec and Sprycel treat Ph+ CML in the advanced and blast phases in adults, or Ph+ ALL, if other drugs didn't work for them.</p>








<p>The use of Gleevec and Sprycel in treating newly diagnosed Ph+ CML in adults has been directly compared in a <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1002315" target="_blank" rel="noopener">clinical study</a>. Researchers compared people who took either 400 mg of Gleevec a day or 100 mg of Sprycel a day.</p>








<p>Within 12 months, 66.2% of people who took Gleevec had no Ph+ cells in their bone marrow (where cancerous CML cells develop). In the group that took Sprycel, 76.8% of the people had no Ph+ cells in their bone marrow.</p>








<p>After five years of treatment, an estimated 89.6% of people who took Gleevec were still alive. That's compared to an estimated 90.9% of people who took Sprycel.</p>








<p>The results of this study suggest that Sprycel may be slightly more effective than Gleevec at treating newly diagnosed Ph+ CML in the chronic phase.</p>








<h3>Costs</h3>








<p>Gleevec and Sprycel are both brand-name drugs. Sprycel doesn't have a generic form, but Gleevec has a generic form called imatinib. Brand-name medications usually cost more than generics.</p>








<p>According to estimates on <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1002315" target="_blank" rel="noopener">GoodRx.com</a>, brand-name Gleevec may cost less than Sprycel. The generic form of Gleevec (imatinib) may also cost less than Sprycel. The actual price you'll pay for either drug depends on your dose, your insurance plan, your location, and the pharmacy you use.</p>








<span class="anchor" id="gleevec-and-alcohol"></span>
<h2>Gleevec and alcohol</h2>








<p>It's not known whether Gleevec and alcohol interact with each other.</p>








<p>However, your liver metabolizes (breaks down) both Gleevec and alcohol. So drinking too much alcohol while you're taking Gleevec may prevent your liver from breaking down the drug. This could raise levels of Gleevec in your body and increase your risk for serious side effects, including liver damage.</p>








<p>Both Gleevec and alcohol can cause side effects such as:</p>








<ul>
<li>nausea</li>








<li>diarrhea</li>








<li>headache</li>








<li>fatigue (lack of energy)</li>








</ul>
<p>Drinking alcohol during your Gleevec treatment could increase your risk of having these side effects.</p>








<p>If you drink alcohol, talk with your doctor about how much is safe for you during your Gleevec treatment.</p>








<span class="anchor" id="interactions"></span>
<!--[MMR]--><!--[END MMR]--><h2>Gleevec interactions</h2>








<p>Gleevec can interact with several other medications. It can also interact with certain supplements as well as certain foods.</p>








<p>Different interactions can cause different effects. For instance, some can interfere with how well a drug works, while others can cause increase side effects.</p>








<h3>Gleevec and other medications</h3>








<p>Below is a list of medications that can interact with Gleevec. This list doesn't contain all drugs that may interact with Gleevec.</p>








<p>Before taking Gleevec, talk with your doctor and pharmacist. Tell them about all prescription, over-the-counter, and other drugs you take. Also tell them about any <a href="/articles/195878.php" title="Vitamins: What are they and what do they do?" class="keywords">vitamins</a>, herbs, and supplements you use. Sharing this information can help you avoid potential interactions.</p>








<p>If you have questions about drug interactions that may affect you, ask your doctor or pharmacist.</p>








<p><strong>Gleevec and Tylenol</strong></p>








<p>Taking Gleevec with Tylenol (acetaminophen) can increase your risk for serious side effects, such as liver damage.</p>








<p>Enzymes (special proteins) in your liver break down both Gleevec and Tylenol. Together, the two drugs can overwhelm the enzymes and damage cells in your liver.</p>








<p>Ask your doctor whether it's safe for you to take Tylenol during your Gleevec treatment.</p>








<p><strong>Gleevec and certain seizure medications</strong></p>








<p>Taking Gleevec with certain seizure medications can decrease Gleevec levels in your body. This can make Gleevec less effective (work less well).</p>








<p>Examples of seizure medications that can decrease Gleevec levels include:</p>








<ul>
<li>phenytoin (Dilantin, Phenytek)</li>








<li>carbamazepine (Carbatrol, Tegretol)</li>








<li>phenobarbital</li>








</ul>
<p>If you're taking Gleevec and certain seizure medications, your doctor may prescribe a different seizure drug or adjust the dosage of Gleevec.</p>








<p><strong>Gleevec and certain antibiotics</strong></p>








<p>Taking Gleevec with certain <a href="/articles/10278.php" title="What to know about antibiotics" class="keywords">antibiotics</a> (drugs that treat bacterial infections) can increase Gleevec levels in your body. Antibiotics prevent Gleevec from breaking down in your body. This increases your risk for serious side effects.</p>








<p>An example of an antibiotic that can increase Gleevec levels is clarithromycin (Biaxin XL).</p>








<p>If you're taking Gleevec and need an antibiotic, your doctor may monitor you for side effects. They may also reduce your Gleevec dosage for a time.</p>








<p><strong>Gleevec and certain antifungals</strong></p>








<p>Taking Gleevec with certain antifungals (drugs that treat fungal infections) can prevent the breakdown of Gleevec in your body. This can raise Gleevec levels in your blood and increase your risk for serious side effects.</p>








<p>Examples of antifungals that can increase Gleevec levels are:</p>








<ul>
<li>itraconazole (Onmel, Sporanox, Tolsura)</li>








<li>ketoconazole (Extina, Ketozole, Xolegel)</li>








<li>voriconazole (Vfend)</li>








</ul>
<p>If you're taking Gleevec and need antifungal treatment, your doctor will monitor you for side effects. They may also reduce your Gleevec dosage for a time.</p>








<p><strong>Gleevec and opioids</strong></p>








<p>Taking Gleevec with certain pain medications can increase levels of the pain reliever in your body. This could make you more likely to have serious side effects such as sedation (feeling drowsy and less alert) and respiratory depression (slow breathing).</p>








<p>Examples of opioid pain medications that can increase Gleevec levels include:</p>








<ul>
<li>oxycodone (Oxycontin, Roxicodone, Xtampza ER)</li>








<li>tramadol (ConZip, Ultram)</li>








<li>methadone (Dolophine, Methadose)</li>








</ul>
<p>Talk with your doctor about whether it's safe to take pain medication during your Gleevec treatment. They may suggest other ways to ease your pain.</p>








<p><strong>Gleevec and certain HIV medications</strong></p>








<p>Taking Gleevec with certain <a href="/articles/17131.php" title="Explaining HIV and AIDS" class="keywords">HIV</a> medications can increase your risk for serious side effects. Certain HIV drugs can prevent Gleevec from breaking down, leading to higher levels of Gleevec in your body.</p>








<p>Examples of HIV medications that can increase Gleevec levels include:</p>








<ul>
<li>atazanavir (Reyataz)</li>








<li>nevirapine (Viramune)</li>








<li>saquinavir (Invirase)</li>








</ul>
<p>Another HIV medication, efavirenz (Sustiva), can decrease levels of Gleevec in your body. This can cause Gleevec to be less effective.</p>








<p>Many HIV medications come as combination tablets, which means they include more than one drug. So be sure to talk with your doctor about all the HIV medications you take.</p>








<p>If you need to take Gleevec with certain HIV medications, your doctor may change your Gleevec dosage.</p>








<p><strong>Gleevec and certain blood pressure medications</strong></p>








<p>Taking Gleevec with certain <a href="/articles/270644.php" title="What is a normal blood pressure?" class="keywords">blood pressure</a> medications can increase or decrease the levels of either drug in your body. This could make you more likely to have side effects or reduce how well the medications work.</p>








<p>Example of these drugs include verapamil (Calan, Tarka).</p>








<p>If you need to take Gleevec with any of these medications, your doctor will monitor you more closely for side effects. They may also adjust the dosage of either medication or recommend a different drug.</p>








<p><strong>Gleevec and warfarin</strong></p>








<p>Taking Gleevec with warfarin (Coumadin, Jantoven) can increase your risk for bleeding. Gleevec prevents warfarin from breaking down in your body. This increases levels of warfarin and can lead to bleeding that's hard to control.</p>








<p>If you need an anticoagulant (blood thinner) while taking Gleevec, your doctor will likely prescribe a drug other than warfarin.</p>








<div id="threequarter-of-article"></div>
<h3>Gleevec and St. John's wort</h3>








<p>Taking Gleevec with St. John's wort can decrease levels of Gleevec in your body. This can make Gleevec less effective (not work as well).</p>








<p>Ask your doctor whether St. John's wort is safe for you to take during your Gleevec treatment. They may recommend an alternative to St. John's Wort or increase your Gleevec dose.</p>








<h3>Gleevec and grapefruit</h3>








<p>Eating grapefruit or drinking grapefruit juice during your Gleevec treatment can increase your risk for serious side effects. Grapefruit contains chemicals that prevent Gleevec from breaking down in your body. This causes increased levels of Gleevec, which can lead to more severe side effects.</p>








<p>Be sure to avoid eating grapefruit and drinking grapefruit juice during your Gleevec treatment.</p>








<span class="anchor" id="how-to-take-"></span>
<h2>How to take Gleevec</h2>








<p>Be sure to take Gleevec according to your doctor or healthcare provider's instructions.</p>








<h3>When to take</h3>








<p>For Gleevec doses of 600 mg or less, the drug should be taken once a day. You can take it at any time.</p>








<p>If your doctor prescribes 800 mg of Gleevec a day, you'll take it in two doses: 400 mg in the morning and 400 mg in the evening.</p>








<p>Your doctor will give you instructions on when you should take your dose.</p>








<h3>Taking Gleevec with food</h3>








<p>Take Gleevec with a meal and a large glass of water. This can help prevent an <a href="/articles/163484.php" title="What to know about indigestion or dyspepsia" class="keywords">upset stomach</a>.</p>








<h3>Can Gleevec be crushed, split, or chewed?</h3>








<p>You shouldn't crush, split, or chew Gleevec tablets. Crushed and split tablets can be harmful to any skin or other body parts that come in contact with them.</p>








<p>If you have trouble swallowing Gleevec tablets, place the tablet in a large glass of water or apple juice. Stir the water with a spoon to help the tablet dissolve. Then drink the mixture right away.</p>








<span class="anchor" id="how-it-works"></span>
<h2>How Gleevec works</h2>








<p>Gleevec contains the drug imatinib, which belongs to a class of drugs called tyrosine kinase inhibitors (TKIs). Medications in the TKI drug class are targeted therapies. They affect very specific proteins in cancer cells.</p>








<p>Gleevec is approved to treat several different conditions. Here we'll explore how Gleevec works to treat two of them.</p>








<h3>For Ph+ CML</h3>








<p>In Philadelphia-positive (Ph+) chronic myeloid leukemia (CML), the cells that create white blood cells have a mistake in their genetic makeup. This genetic mistake is found on a DNA strand called the Philadelphia chromosome.</p>








<p>The Philadelphia chromosome contains an abnormal gene (BCR-ABL1) that causes too many white blood cells to form. These white blood cells don't mature and die like they're supposed to. Immature white blood cells called "blasts" crowd out other types of blood cells that your blood needs to work correctly.</p>








<p>Gleevec works by attaching to a protein, called tyrosine kinase, in cells made by BCR-ABL1. When Gleevec binds to this protein, the drug prevents the cell from sending signals that tell the cell to grow. Without these growth signals, the cancerous blood cells die. This helps restore the number of blast cells to a healthier number.</p>








<h3>For GIST</h3>








<p>Gleevec also helps treat gastrointestinal stromal tumors (GIST). In many GIST tumor cells, there are a higher number of certain proteins, called Kit and platelet-derived growth factor (PDGF), than in normal cells. These proteins help cancer cells grow and divide.</p>








<p>Gleevec targets these proteins and prevents them from working. This slows the growth of cancer. It also causes cancer cells to die.</p>








<h3>How long does it take to work?</h3>








<p>It depends. The timing of when Gleevec starts to work is different for each person.</p>








<p><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">Clinical studies</a> looked at people with CML who took Gleevec. In one month, the number of cancerous cells in the blood was reduced in about half of the people in the blast crisis stage (advanced stage of CML). In <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">studies</a> of people with GIST who took Gleevec, the tumors stopped growing or shrank in three months.</p>








<p>Your doctor will routinely monitor your blood to see if Gleevec is working for you.</p>








<span class="anchor" id="pregnancy"></span>
<!--[DLB]--><!-- Leaderboard BANNER advert -->

<div id="dlb3_container" class="mnt css_c4zij" >


<!-- header_ad code -->
<div class="mnt_history" style="display:none;">

	<a href="/whitelist-mnt"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_history_leaderboard.png" alt="Thank you for supporting Medical News Today"/></a>


</div>
    <div id='dlb3_unit' adonis-marker>
	<script type='text/javascript'>
		googleAdSlotInfo.push({
			"slotName":'DLB3',
			"slotContainer":'dlb3_container'		});
	</script>
	</div>
	

</div>






<!-- /header_ad code --><!--[END DLB]--><h2>Gleevec and pregnancy</h2>








<p>You should avoid Gleevec if you're pregnant. There have been <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">reports</a> of miscarriages and harm to the fetus in women who took Gleevec while pregnant. And in <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">animal studies</a>, pregnant females who were given Gleevec had an increased risk for birth defects.</p>








<p>If you're pregnant, your doctor may advise you to wait until after you've given birth to start taking Gleevec. Or they will recommend a different drug.</p>








<p>If you're taking Gleevec, it's important to use effective <a href="/articles/162762.php" title="What types of birth control are there?" class="keywords">birth control</a> so you don't become pregnant. After you take your last dose of Gleevec, keep using birth control for 14 days.</p>








<span class="anchor" id="breastfeeding"></span>
<!--[MMR]--><!--[END MMR]--><h2>Gleevec and breastfeeding</h2>








<p><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">Studies</a> show that Gleevec passes into human breast milk. This can cause serious harm to a breastfeeding infant.</p>








<p>If you're breastfeeding and considering taking Gleevec, your doctor may advise you to stop breastfeeding when you start treatment.</p>








<p>After you take your last dose of Gleevec, wait at least one month before you start breastfeeding.</p>








<span class="anchor" id="overdose"></span>
<h2>Gleevec overdose</h2>








<p>Taking too much Gleevec can increase your risk for serious side effects.</p>








<h3>Overdose symptoms</h3>








<p>Symptoms of an overdose can include:</p>








<ul>
<li>nausea</li>








<li>vomiting</li>








<li>diarrhea</li>








<li>belly pain</li>








<li>severe rash</li>








<li>muscle spasms (twitches)</li>








<li>headache</li>








<li>lack of appetite</li>








<li>muscle weakness</li>








<li>fatigue (lack of energy)</li>








<li>swelling</li>








<li>blood disorders, such as low levels of platelets, red blood cells, or white blood cells</li>








<li>fever</li>








</ul>
<h3>What to do in case of overdose</h3>








<p>If you think you've taken too much of this drug, call your doctor. You can also call the American Association of Poison Control Centers at 800-222-1222 or use their <a href="https://www.poisonhelp.org/help" target="_blank" rel="noopener">online tool</a>. <strong>But if your symptoms are severe, call 911 or go to the nearest emergency room right away.</strong></p>








<span class="anchor" id="faqs"></span>
<h2>Common questions about Gleevec</h2>








<p>Here are answers to some frequently asked questions about Gleevec.</p>








<h3>Is Gleevec a type of chemotherapy?</h3>








<p>Gleevec isn't technically a form of chemotherapy. Gleevec is a targeted therapy that affects specific molecules in cancer cells.</p>








<p>By singling out specific molecules, targeted therapies like Gleevec help slow the growth and spread of cancer cells. Your doctor will typically prescribe a targeted therapy for you based on the type of cancer you have.</p>








<p>Chemotherapy drugs are different from targeted therapies. Chemotherapy medications act on all cells in the body that are rapidly growing, not just cancer cells. Chemotherapy drugs usually kill the growing cells and affect more cells in the body than targeted therapy does.</p>








<h3>Is the generic form of Gleevec as effective as the brand-name drug?</h3>








<p>The Food and Drug Administration (FDA) requires the makers of generic drugs to prove that their product has:</p>








<ul>
<li>the same active ingredient as the brand-name drug</li>








<li>the same strength and dosage form as the brand-name drug</li>








<li>the same route of administration (how you take the drug)</li>








</ul>
<p>The generic drug is also required to work in the same way and just as well as the brand-name product.</p>








<p>According to the FDA, the generic form of Gleevec meets these requirements. This means that the FDA guarantees that the generic form is as effective as the brand-name drug.</p>








<h3>Can I develop resistance to treatment with Gleevec?</h3>








<p>Yes. It's possible for you to develop resistance to Gleevec. Resistance means that the drug stops working over time. It's thought that this is caused by a change in the genes of cancer cells.</p>








<p>If you develop resistance to Gleevec, your doctor may prescribe a higher dose. They'll see if the cancer cells respond again to the medication. Your doctor may also prescribe a different drug that you don't have resistance to.</p>








<h3>Are there dietary restrictions I should follow while taking Gleevec?</h3>








<p>There are no formal dietary restrictions that you should follow while taking Gleevec. However, you should avoid eating grapefruit and drinking grapefruit juice. Grapefruit contains a chemical that can prevent your body from metabolizing (breaking down) Gleevec. This can lead to higher levels of the drug in your blood. Levels of Gleevec that are higher than normal increase your risk for serious side effects.</p>








<p>In addition, your doctor may give you general advice on your diet to help ease certain side effects. For example, Gleevec causes nausea and vomiting in many people. To help prevent this, your doctor may recommend that you avoid foods that can make nausea worse. These include heavy, greasy, or fatty foods, and spicy or acidic foods. Examples are most red sauces, fried foods, and many fast food items.</p>








<p>Finally, if you're taking Gleevec for a gastrointestinal cancer, such as gastrointestinal stromal tumors (GIST), your doctor may recommend specific dietary restrictions. The goal is to prevent problems in your stomach or intestines. Talk with your doctor about which foods are best for you.</p>








<h3>Will I have withdrawal symptoms if I stop using Gleevec?</h3>








<p>You might. Some people have had withdrawal symptoms after ending their Gleevec treatment. In one small <a href="https://ascopubs.org/doi/10.1200/JCO.2014.55.6910" target="_blank" rel="noopener">clinical study</a>, 30% of people had muscle or bone pain after stopping Gleevec. The pain was most often in their shoulders, hips, legs, and arms. This withdrawal symptom occurred within one to six weeks of stopping treatment.</p>








<p>About half of the people treated their pain with over-the-counter pain relievers. The other half needed prescription medication. In most people who had these withdrawal symptoms, muscle and bone pain went away within three months to a year or longer.</p>








<h3>Will I need to use other drugs with Gleevec for treatment?</h3>








<p>It depends on how advanced your cancer is. For advanced stages of cancer or cancers that have spread to the brain or spine, your doctor may add chemotherapy to your Gleevec treatment. In addition, children with Philadelphia-positive (Ph+) acute lymphocytic leukemia (ALL) may receive Gleevec along with chemotherapy.</p>








<p>For certain types of cancers, your doctor may also prescribe a steroid. And you may need to use medications to manage side effects, such as pain relievers for muscle pain.</p>








<span class="anchor" id="expiration"></span>
<h2>Gleevec expiration, storage, and disposal</h2>








<p>When you get Gleevec from the pharmacy, the pharmacist will add an expiration date to the label on the bottle. This date is typically one year from the date they dispensed the medication.</p>








<p>The expiration date helps guarantee the effectiveness of the medication during this time. The <a href="https://www.fda.gov/drugs/special-features/dont-be-tempted-use-expired-medicines" target="_blank" rel="noopener">current stance</a> of the Food and Drug Administration (FDA) is to avoid using expired medications. If you have unused medication that has gone past the expiration date, talk with your pharmacist. They can tell you whether you might still be able to use it.</p>








<h3>Storage</h3>








<p>How long a medication remains good can depend on many factors, including how and where you store the medication.</p>








<p>Store your Gleevec pills at room temperature in a tightly sealed container. Be sure to protect them from moisture.</p>








<h3>Disposal</h3>








<p>If you no longer need to take Gleevec and have leftover medication, it's important to dispose of it safely.</p>








<p>This helps prevent others, including children and pets, from taking the drug by accident. It also helps keep the drug from harming the environment.</p>








<p>The <a href="https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know" target="_blank" rel="noopener">FDA website</a> provides several useful tips on medication disposal. You can also ask your pharmacist for information on how to dispose of your medication.</p>








<span class="anchor" id="for-professionals"></span>
<!--[DLB]--><!-- Leaderboard BANNER advert -->

<div id="dlb4_container" class="mnt css_c4zij" >


<!-- header_ad code -->
<div class="mnt_history" style="display:none;">

	<a href="/whitelist-mnt"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_history_leaderboard.png" alt="Thank you for supporting Medical News Today"/></a>


</div>
    <div id='dlb4_unit' adonis-marker>
	<script type='text/javascript'>
		googleAdSlotInfo.push({
			"slotName":'DLB4',
			"slotContainer":'dlb4_container'		});
	</script>
	</div>
	

</div>






<!-- /header_ad code --><!--[END DLB]--><!--[MMR]--><!--[END MMR]--><h2>Professional information for Gleevec</h2>








<p>The following information is provided for clinicians and other healthcare professionals.</p>








<h3>Indications</h3>








<p>Gleevec (imatinib) is FDA-approved to treat the following:</p>








<ul>
<li>adults and children with newly diagnosed Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase</li>








<li>adults with Ph+ CML in any phase, following failure of interferon-alpha therapy</li>








<li>adults with relapsed or refractory Ph+ acute lymphocytic leukemia (ALL)</li>








<li>children with newly diagnosed Ph+ ALL in combination with chemotherapy</li>








<li>adults with myelodysplastic/myeloproliferative disease associated with platelet-derived growth factor receptor gene rearrangements</li>








<li>adults with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown</li>








<li>adults with hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFRα fusion kinase, negative for the FIP1L1-PDGFRα fusion kinase, or unknown status</li>








<li>adults with unresectable, recurrent, or metastatic dermatofibrosarcoma protuberans (DFSP)</li>








<li>adults with unresectable or metastatic malignant Kit+ gastrointestinal stromal tumors (GIST)</li>








<li>adjuvant therapy for adults with Kit+ GIST following complete gross resection</li>








</ul>
<h3>Mechanism of action</h3>








<p>Gleevec inhibits the BCR-ABL tyrosine kinase, which is the abnormal tyrosine kinase found in Ph+ CML. Inhibition of BCR-ABL tyrosine kinase prevents cellular proliferation and induces apoptosis in BCR-ABL cell lines and in leukemic cell lines. Gleevec also inhibits the tyrosine kinases for platelet-derived growth factor (PDGF) and <a href="/info/stem_cell/" title="What are Stem Cells?" class="keywords">stem cell</a> factor (SCF) as well as c-Kit, which inhibits proliferation and induces apoptosis in GIST cells.</p>








<h3>Pharmacokinetics and metabolism</h3>








<p>Mean absolute bioavailability is 98% following oral administration. Approximately 95% of dose is bound to plasma proteins (mostly albumin and α1-acid glycoprotein).</p>








<p>Metabolism occurs primarily via CYP3A4 to an active metabolite, with minor metabolism occurring via CYP1A2, CYP2D6, CYP2C9, and CYP2C19. The main circulating active metabolite is formed primarily by CYP3A4. Approximately 68% is eliminated in the feces, with 13% in the urine. Elimination half-life of unchanged drug is 18 hours and elimination half-life of major active metabolite is 40 hours.</p>








<h3>Contraindications</h3>








<p>There are no absolute contraindications to Gleevec use.</p>








<h3>Storage and handling</h3>








<p>Gleevec tablets should be stored at room temperature (77°F/25°C) in a tightly-sealed container. Protect tablets from moisture.</p>








<p>Gleevec tablets are considered hazardous, according to <a href="https://www.osha.gov/SLTC/hazardousdrugs/index.html" target="_blank" rel="noopener">Occupational Safety and Health Administration (OSHA) standards</a>. Tablets should not be crushed. Avoid touching crushed tablets. If skin or mucus membranes come in contact with crushed tablets, wash the affected area according to OSHA guidance.</p>








<p><strong>Disclaimer:</strong> Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up-to-date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.</p>
<div id="bottom-of-article"></div>
 	</div> 	</div> 
<style type="text/css">
		/*.mnt_dlb_foot_container { display:block; width: 728px; height: 90px; }*/
		/*@media (min-width: 990px) { .mnt_dlb_foot_container { display: none; } }
		@media (min-width:1148px) { .mnt_dlb_foot_container { display:block;} }*/
</style>
<!-- MNT_Adsense_Desktop_728x90 Footer -->
<ins class="adsbygoogle mnt_dlb_foot_container"
	 id="mnt_dlb_foot_container"
     style="display:inline-block;width:728px;height:90px"
     data-ad-client="ca-pub-4771166113579725"
     data-ad-slot="9436500920"></ins>


<script>


	fireOrSaveJsFunctions(1,function(){loadScript(
		"//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js",
		{},
		function(){}

	)});


</script>
<script>(adsbygoogle = window.adsbygoogle || []).push({});</script>



<p id='slidebox_trigger'></p>

	<div id="suggest_reading_outer_container" class="place full">

		<h2 class="suggested_reading internal_related">Related coverage</h2>
	<span></span>
		<!--<h2 class="suggested_reading">Suggested Reading</h2>-->
	
	<div itemscope itemtype="http://schema.org/WebPage"> <!-- suggested_reading_container_parent -->
	<div class="suggested_reading_container ">
				<div class='suggested_reading_inner column1'>
				<div class="suggested_item">
		<a href="/articles/325332.php" title="Is leukemia hereditary?" class="related_coverage_link" data-id="325332">
				<div class="suggested_item_image">
			<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/325/325332/325332_1100.jpg" alt="" />
		</div>
				<span class="title">Is leukemia hereditary?</span>
		<span class="summary">Leukemia is a genetic condition, but in most cases, it is not hereditary. In this article, we explore the links between leukemia and family history, genetics, and lifestyle and environmental factors.</span>
		
			<span class="more">Read now</span>
			</a>
	</div> 				</div>
						<div class='suggested_reading_inner column2'>
				<div class="suggested_item">
		<a href="/articles/142595.php" title="Leukemia: What you need to know" class="related_coverage_link" data-id="142595">
				<div class="suggested_item_image">
			<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/142/142595/142595_1100.jpg" alt="" />
		</div>
				<span class="title">Leukemia: What you need to know</span>
		<span class="summary">Leukemia is a cancer caused by an overproduction of damaged white blood cells. It is common in children, but leukemia most often occurs in adults older than 55. The outlook depends on the type of the disease. Find out more about these types, as well as early symptoms, risk factors, and ways to manage this illness.</span>
		
			<span class="more">Read now</span>
			</a>
	</div> 				</div>
						<div class='suggested_reading_inner column3'>
				<div class="suggested_item">
		<a href="/articles/322756.php" title="What is the outlook for chronic lymphocytic leukemia?" class="related_coverage_link" data-id="322756">
				<div class="suggested_item_image">
			<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/322/322756/322756_1100.jpg" alt="" />
		</div>
				<span class="title">What is the outlook for chronic lymphocytic leukemia?</span>
		<span class="summary">Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. Although doctors can very rarely cure CLL, survival rates for this cancer are typically good. A person’s life expectancy for CLL depends on how far the cancer has progressed and when they receive treatment. Learn more here.</span>
		
			<span class="more">Read now</span>
			</a>
	</div> 				</div>
						<div class='suggested_reading_inner column4'>
				<div class="suggested_item">
		<a href="/articles/323486.php" title="What are the symptoms of skin cancer?" class="related_coverage_link" data-id="323486">
				<div class="suggested_item_image">
			<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/323/323486/323486_1100.jpg" alt="" />
		</div>
				<span class="title">What are the symptoms of skin cancer?</span>
		<span class="summary">Skin cancer is the most common cancer in the United States. People should check every month for signs of melanoma and other skin cancers. In this article, we take a close look at the types of skin cancer and the symptoms to look for. We also discuss risk factors and prevention.</span>
		
			<span class="more">Read now</span>
			</a>
	</div> 				</div>
				</div>
	</div>
	</div>
	

<div id="social_bottom"  >			
    <div id="share_social_bottom">    
        <div id="article_social_bottom_facebook" ></div>
        <div id="article_social_bottom_twitter" ></div>
        <div id="article_social_bottom_linkedin" ></div>

		    
    </div>
    <div class="toolbox">
		<div class="email">            <a rel="nofollow" title="email this article" href="#">
			<span class="toolbox_label">email</span></a>
            <span class="visuallyhidden">
            <a rel="nofollow" title="email this article" href="#">email</a>
            </span>
        </div>        
		        <div class="print">			            <a id="9d0a8cb89fe05c5ce8c77f6553faca1f" href="#" rel="nofollow" title="View print preview" target="_blank">
			<span class="toolbox_label">print</span></a>
        </div>        		
		<div class="share">            <a rel="nofollow" title="share this article" href="#">
			<span class="toolbox_label">share</span></a>
            <span class="visuallyhidden">
            <a rel="nofollow" title="share this article" href="#">share</a>
            </span>
        </div>

    </div>

</div><a id="rate-this-article"></a>	<div class="article_category_container">
					<div class="article_main_category_container"> 
				<span itemprop="genre" class="category_main">
				<a href="/categories/cancer-oncology" title="Cancer / Oncology News" class="current">Cancer / Oncology</a>
				</span>
			</div> 					<div class="article_sub_category_container">
					<span itemprop="genre" class="category_sub">
			<a href="/categories/blood" title="Blood / Hematology News" class="current">Blood / Hematology</a>
			</span>
						<span itemprop="genre" class="category_sub">
			<a href="/categories/gastrointestinal" title="GastroIntestinal / Gastroenterology News" class="current">GastroIntestinal / Gastroenterology</a>
			</span>
						<span itemprop="genre" class="category_sub">
			<a href="/categories/melanoma" title="Melanoma / Skin Cancer News" class="current">Melanoma / Skin Cancer</a>
			</span>
					</div> 	</div> 	                    <div class="widget_citation_group" id="widget_citation">

                        <div class="panel widget_citation_panel">
                            <div class="panel-heading widget_citation_heading active">
                                <h4 class="panel-title">
                                    <a data-toggle="collapse" data-parent="#widget_citation" href="#additional">
                                        Additional information</a>
                                </h4>
                            </div>
                            <div id="additional" class="panel-collapse collapse in">
                                <div class="panel-body widget_citation_body">
                                    	<ul id="additional" >

		<p> Article last reviewed by Sun  9 June 2019.<br><br>Visit our <a href='/categories/cancer-oncology' title='Visit our Cancer / Oncology category page'>Cancer / Oncology</a> category page for the latest news on this subject, or <a href='/newsletter' title='Sign up to our newsletter'>sign up to our newsletter</a> to receive the latest updates on Cancer / Oncology.<br><br>All references are available in the <b>References</b> tab.		</p>
	</ul>
	                                </div>
                            </div>
                        </div>


                        <div class="panel widget_citation_panel">
                            <div class="panel-heading widget_citation_heading">
                                <h4 class="panel-title">
                                    <a data-toggle="collapse" data-parent="#widget_citation" href="#references">
                                        References</a>
                                </h4>
                            </div>
                            <div id="references" class="panel-collapse collapse">
                                <div class="panel-body widget_citation_body">
                                    	<ul id="references" >
		<noscript> 
		This content requires JavaScript to be enabled.<br/><br/> 
		</noscript>
		<p>
		<p>The American Cancer Society medical and editorial content team. (2017). Targeted therapy for gastrointestinal stromal tumor. <a href="https://www.cancer.org/cancer/gastrointestinal-stromal-tumor/treating/targeted-therapy.html" target="_blank" rel="noopener">https://www.cancer.org/cancer/gastrointestinal-stromal-tumor/treating/targeted-therapy.html</a></p>
<p>The American Cancer Society medical and editorial content team. (2018). How do you know if treatment for chronic myeloid leukemia is working? <a href="https://www.cancer.org/cancer/chronic-myeloid-leukemia/treating/is-treatment-working.html" target="_blank" rel="noopener">https://www.cancer.org/cancer/chronic-myeloid-leukemia/treating/is-treatment-working.html</a></p>
<p>The American Cancer Society medical and editorial content team. (2018). Phases of chronic myeloid leukemia. <a href="https://www.cancer.org/cancer/chronic-myeloid-leukemia/detection-diagnosis-staging/staging.html" target="_blank" rel="noopener">https://www.cancer.org/cancer/chronic-myeloid-leukemia/detection-diagnosis-staging/staging.html</a></p>
<p>ClinicalTrials.gov. (2018). Imatinib treatment in recent onset type 1 diabetes. <a href="https://clinicaltrials.gov/ct2/show/study/NCT01781975" target="_blank" rel="noopener">https://clinicaltrials.gov/ct2/show/study/NCT01781975</a></p>
<p>Don’t be tempted to use expired medicines. (2016). <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm481139.htm" target="_blank" rel="noopener">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm481139.htm</a></p>
<p>Gleevec - imatinib mesylate tablet. (2018). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b</a></p>
<p>GoodRx. (n.d.). <a href="https://www.goodrx.com/" target="_blank" rel="noopener">https://www.goodrx.com/</a></p>
<p>Hazardous drugs. (n.d.). <a href="https://www.osha.gov/SLTC/hazardousdrugs/index.html" target="_blank" rel="noopener">https://www.osha.gov/SLTC/hazardousdrugs/index.html</a></p>
<p>Hochhaus A, et al. (2017). Long-term outcomes of imatinib treatment for chronic myeloid leukemia. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1609324" target="_blank" rel="noopener">https://www.nejm.org/doi/full/10.1056/NEJMoa1609324</a></p>
<p>Kantarjian H, et al. (2010). Dasatinib versus imatinib newly diagnosed chronic-phase chronic myeloid leukemia. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1002315" target="_blank" rel="noopener">https://www.nejm.org/doi/full/10.1056/NEJMoa1002315</a></p>
<p>Kockan B, et al. (2017). Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia. <a href="https://www.spandidos-publications.com/ol/15/2/2419" target="_blank" rel="noopener">https://www.spandidos-publications.com/ol/15/2/2419</a></p>
<p>NCCN guidelines for patients: Chronic myeloid leukemia. (2018). <a href="https://www.nccn.org/patients/guidelines/cml/" target="_blank" rel="noopener">https://www.nccn.org/patients/guidelines/cml/</a></p>
<p>NCCN Guidelines for patients: Melanoma. (2018). <a href="https://www.nccn.org/patients/guidelines/melanoma/index.html" target="_blank" rel="noopener">https://www.nccn.org/patients/guidelines/melanoma/index.html</a></p>
<p>Raut CP, et al. (2018). Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: The PERSIST-5 clinical trial. <a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2711891" target="_blank" rel="noopener">https://jamanetwork.com/journals/jamaoncology/article-abstract/2711891</a></p>
<p>Richter J, et al. (2014). Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: A tyrosine kinase inhibitor withdrawal syndrome? <a href="https://ascopubs.org/doi/10.1200/JCO.2014.55.6910" target="_blank" rel="noopener">https://ascopubs.org/doi/10.1200/JCO.2014.55.6910</a></p>
<p>Saglio G, et al. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0912614" target="_blank" rel="noopener">https://www.nejm.org/doi/full/10.1056/NEJMoa0912614</a></p>
<p>Sprycel - dasatinib tablet. (2018). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df</a></p>
<p>Targeted cancer therapies. (2019). <a href="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet" target="_blank" rel="noopener">https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet</a></p>
<p>Tasigna - nilotinib capsule. (2018). <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146" target="_blank" rel="noopener">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146</a></p>
<p>Vogelhuber M, et al. (2015). Biomodulatory treatment of patients with castration-resistant prostate cancer: A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449347/" target="_blank" rel="noopener">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449347/</a></p>		</p>
	</ul>
	                                </div>
                            </div>
                        </div>


                        <div class="panel widget_citation_panel">
                            <div class="panel-heading widget_citation_heading">
                                <h4 class="panel-title">
                                    <a data-toggle="collapse" data-parent="#widget_citation" href="#citations">
                                        Citations</a>
                                </h4>
                            </div>
                            <div id="citations" class="panel-collapse collapse">
                                <div class="panel-body widget_citation_body">
                                    	<ul id="citations" >
		<p>Please use one of the following formats to cite this article in your essay, paper or report:</p><p><strong>MLA</strong><br />Slowiczek, Lindsay. "Gleevec (imatinib)." <i>Medical News Today</i>. MediLexicon, Intl., 15 Aug. 2019. Web.<br>6 Sep. 2019. &lt;https://www.medicalnewstoday.com/articles/325696.php&gt;</p><hr size="1" /><p><strong>APA</strong><br />Slowiczek, L. (2019, August 15). "Gleevec (imatinib)." <i>Medical News Today</i>. Retrieved from<br><a href='https://www.medicalnewstoday.com/articles/325696.php' itemprop='url'>https://www.medicalnewstoday.com/articles/325696.php</a>.</p><hr size="1" /><p>Please note: If no author information is provided, the source is cited instead.</p>	</ul>
	                                </div>
                            </div>
                        </div>

                    </div>


					
	<hr class="nonprint"/>
<div class="article_email">
	<div id="header_close_button" class="email_close"></div>
	<div class="emailform_container">

	</div>
</div></div>  
</article>

	<div class="col-xs-12 col-sm-12 col-md-4 col-lg-4 sidebar"> 
<!-- article_ad code -->
<!-- MREC ARTICLE advert -->
<div id="dmr1_container" class="mnt css_hs211">

<div class="mnt_history" style="display:none;">
	<a href="/knowledge-center"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_knowledge_center_001.png" alt="MNT Knowledge Center" /></a>
 	

</div>

		<div id='dmr1_unit' adonis-marker>
		<script type='text/javascript'>
			googleAdSlotInfo.push({
				"slotName":'DMR1',
				"slotContainer":'dmr1_container'			});
		</script>
		</div>
		<span class='bt-uid-tg' data-uid='5b84643d24-160' style='display: none !important'></span></div> <!-- /article_ad code -->
	<div id="sidebar_feature" class="full">
			<h2>Latest news</h2>
		<span></span>
	<ul class="sidebar_feature">
	<li>	<a href="/articles/326281.php" title="Curiosities of medical history: Trepanation">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326281/326281_1100.jpg" alt="Curiosities of medical history: Trepanation" class="original">
	<div class="headline">Curiosities of medical history: Trepanation</div> 
	<div class="excerpt">Trepanation is the historical practice of drilling holes into the skull. But why did our ancestors do it, and when did it start? We investigate.</div>
	</div>

	</a></li>
	<li>	<a href="/articles/326278.php" title="Scientists identify genetic components of left-handedness">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326278/326278_1100.jpg" alt="Scientists identify genetic components of left-handedness" class="original">
	<div class="headline">Scientists identify genetic components of left-handedness</div> 
	<div class="excerpt">In a genetic analysis of 400,000 people, scientists have, for the first time, identified four DNA regions associated with left-handedness.</div>
	</div>

	</a></li>
	<li>	<a href="/articles/326243.php" title="World first: Doctors use 'reprogrammed' stem cells to repair cornea">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326243/326243_1100.jpg" alt="World first: Doctors use 'reprogrammed' stem cells to repair cornea" class="original">
	<div class="headline">World first: Doctors use 'reprogrammed' stem cells to repair cornea</div> 
	<div class="excerpt">In a groundbreaking procedure, surgeons have successfully repaired a human cornea using 'reprogrammed' cells from the patient's skin. </div>
	</div>

	</a></li>
	<li>	<a href="/articles/326232.php" title="Inflammation in late teens linked to mortality risk decades later">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326232/326232_1100.jpg" alt="Inflammation in late teens linked to mortality risk decades later" class="original">
	<div class="headline">Inflammation in late teens linked to mortality risk decades later</div> 
	<div class="excerpt">Experts know little about how inflammation in early life affects health later on. A new study links teen inflammation to mortality risk 35 years later.</div>
	</div>

	</a></li>
	<li>	<a href="/articles/326271.php" title="Scientists identify a trigger for type 1 diabetes in mice">
	<div>

	<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe/WZNAAAADklEQVR42mNkgAJGDAYAAFEABCaLYqoAAAAASUVORK5CYII=" data-src="https://cdn-prod.medicalnewstoday.com/content/images/hero/326/326271/326271_1100.jpg" alt="Scientists identify a trigger for type 1 diabetes in mice" class="original">
	<div class="headline">Scientists identify a trigger for type 1 diabetes in mice</div> 
	<div class="excerpt">Scientists discover a previously unknown switch that causes immune cells to begin destroying insulin, resulting in the onset of type 1 diabetes. </div>
	</div>

	</a></li>
		</ul>
	</div>
		<!-- article_ad code -->
<!-- MREC ARTICLE advert -->
<div id="dmr2_container" class="mnt css_hs211">

<div class="mnt_history" style="display:none;">
	<a href="/knowledge-center"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/mnt_ads/mnt_knowledge_center_001.png" alt="MNT Knowledge Center" /></a>
 	

</div>

		<div id='dmr2_unit' adonis-marker>
		<script type='text/javascript'>
			googleAdSlotInfo.push({
				"slotName":'DMR2',
				"slotContainer":'dmr2_container'			});
		</script>
		</div>
		<span class='bt-uid-tg' data-uid='5b846454f2-160' style='display: none !important'></span></div> <!-- /article_ad code -->
	<div class="full popular_tabs_container"> 	<div class="full popular_tabs_parent"> 	<h2 class="popular_tabs_heading"><span>Popular in: </span>Cancer / Oncology</h2><span></span>
	<div id="popular_tabs">
	<div class="centered">
	
	<ul class="nav">
		</ul>
	
			<div class="list-wrap">
					<ul id="popular-read">
				<li class="knowledge">
	<a href="/articles/323648.php" title="What to know about cancer">
		<span class="headline">
	What to know about cancer	</span>
		</a></li>
		<li class="knowledge">
	<a href="/articles/323448.php" title="Cancer ribbon colors: A guide">
		<span class="headline">
	Cancer ribbon colors: A guide	</span>
		</a></li>
		<li class="knowledge">
	<a href="/articles/324745.php" title="CBD for cancer: Everything you need to know">
		<span class="headline">
	CBD for cancer: Everything you need to know	</span>
		</a></li>
		<li class="knowledge">
	<a href="/articles/324193.php" title="The best cancer-fighting foods">
		<span class="headline">
	The best cancer-fighting foods	</span>
		</a></li>
		<li class="knowledge">
	<a href="/articles/324950.php" title="What to know about lip cancer">
		<span class="headline">
	What to know about lip cancer	</span>
		</a></li>
				<span></span> 			</ul>
					</div> <!-- /list_wrap -->
			</div> <!-- /the_tabs -->
	</div> <!-- /centered -->
	</div> 	</div> 	</div> <!-- /sidebar -->
</div> 
</div> 


	<img height="1" width="1" src="https://d.turn.com/r/dd/id/L21rdC84MTYvY2lkLzE3NDc2NjAwNjEvdC8y/kv/CampaignID=MedicalNewsToday,Content=leukemiacml">

<div id="message"><a href="#top" style="display: none;">Scroll to top</a></div>


<footer>

<div class="container">

	<div class="row"> 	
		<div class="col-xs-12 col-sm-12 col-md-12 col-lg-12 footer"> 		
			<div id="footer_logo">
				<a href="/"  title="Medical News Today : Home">
					<img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://cdn-prod.medicalnewstoday.com/structure/images/logo/logo-mini-2017.png" alt="MNT home">
				</a>
			</div> 				
			<div id="footer_social">
				<span class="footer_facebook fa-stack fa-lg">
				<a href="https://www.facebook.com/MedicalNewsToday" rel="noopener noreferrer" target="_blank">
				<i class="fa fa-facebook fa-stack-1x fa-inverse"></i>
				</a></span>
				<span class="footer_twitter fa-stack fa-lg">
				<a href="https://twitter.com/mnt" target="_blank" rel="noopener noreferrer">
				<i class="fa fa-twitter fa-stack-1x fa-inverse"></i>
				</a></span>
				<span class="footer_linkedin fa-stack fa-lg">
				<a href="https://www.linkedin.com/company/mednewstoday" rel="noopener noreferrer" target="_blank">
				<i class="fa fa-linkedin fa-stack-1x fa-inverse"></i>
				</a></span>
				<span class="footer_pinterest fa-stack fa-lg">
				<a href="https://www.pinterest.com/search/pins/?q=www.medicalnewstoday.com" rel="noopener noreferrer" target="_blank">
				<i class="fa fa-pinterest fa-stack-1x fa-inverse"></i>
				</a></span>
			</div> 		
			<div id="footer_list">
				<ul>
								<li><a href="/popular" title="View our most popular news articles">Popular news</a></li>
				<li><a href="/archive" title="View all our editorial articles">Editorial articles</a></li>
				<li><a href="/categories" accesskey="m" title="View our complete news category list">All news topics</a></li>
				<li><a href="/knowledge-center" title="Medical conditions and information center">Knowledge center</a></li>

								<li><a href="/newsletter" title="Medical News Today in your inbox">Newsletters</a></li>


					
				<li><a href="/share-our-content" title="Share our content">Share our content</a></li>

								<li><a href="/about" title="About Medical News Today">About us</a></li>
				<li><a href="/authors" title="Our editorial team">Our editorial team</a></li>
				<li><a href="/contact" title="Contact the Medical News Today team">Contact us</a></li>
				<li><a href="/advertising" title="Advertise with Medical News Today">Advertise with MNT</a></li>
				</ul>
			</div> 				
			<span class="footer_separator">
				<span></span>
			</span> 			
			<div id="footer_newsletter">
					<h3 id="footer_newsletter_h3">get our newsletter</h3>
					<span id="footer_newsletter_span">Health tips, wellness advice and more.</span>
					
					<div class="form-group">
						<form method="post" action="#" name="footerNewsletterSignup" id="footerNewsletterSignup" class="newsletterForm">
						<div>
							<input type="text" name="formEmail" id="EmailAddress" class="newsletterFormEmail" placeholder="Enter your email address" size="25" maxlength="150"/>

							<button type="button"
									data-signup-source="footer_newsletter_link"
									class="btn btn-success btn-lg btn-block btn-footer footer_newsletter_link email-signup-btn new_reg_signup">Subscribe</button>

							<div id="footerNewsletterErrorHolder" class="errorHolder"></div>
							

<p>Your <a href="/privacy-policy" title="Privacy policy">privacy</a> is important to us.</p>

						</div>


						</form>

					</div> 				
			</div> 			
			<span class="footer_separator">
				<span></span>
			</span> 			
			<div id="copyright">
				<div class="honcode_img">
				<a href="https://www.healthonnet.org/HONcode/Conduct.html?HONConduct391155" class="seal" onclick="window.open(this.href); return false;">
				<img src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="https://www.honcode.ch/HONcode/Seal/HONConduct391155_s1.gif" alt="This website is certified by Health On the Net Foundation. Click to verify."></a>
				</div> 				<div class="copyright_text float_left">
					<p>Healthline Media UK Ltd, Brighton, UK.</p>
					<p>&copy; 2004-2019 All rights reserved. MNT is the registered trade mark of Healthline Media. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.</p>
				</div> 				<div class="copyright_text float_right">
					<p><a href="/privacy-policy" title="View our privacy policy" onclick="fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'New Header - Desktop - Footer', eventAction: 'Footer - Privacy policy', eventLabel: 'Footer - Privacy policy' });});" >Privacy</a> |
					<a href="/terms" title="View our terms of use" onclick="fireOrSaveJsFunctions(0,function() {ga('send', 'event', { eventCategory: 'New Header - Desktop - Footer', eventAction: 'Footer - Terms', eventLabel: 'Footer - Terms' });});">Terms</a> |
					<a href="/ad-policy" title="View our advertising policy">Ad policy</a> | 
					<a href="https://www.healthline.com/health/careers" title="Careers" rel="noopener" target="_blank">Careers</a></p>
				</div> 			</div> 			
			<div class="footer_truste_container">
				<div class="footer_truste"><a href="//privacy.truste.com/privacy-seal/validation?rid=b59e7a69-59cd-449f-9af4-2bdba7d346e5" rel="noopener noreferrer" target="_blank"><img style="border: none" src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==" data-src="//privacy-policy.truste.com/privacy-seal/seal?rid=b59e7a69-59cd-449f-9af4-2bdba7d346e5" alt="TRUSTe"></a></div>
			</div> 			
		</div> 	
				
	</div> 
</div> 
<footer>

<div id="print_message">
	<p>This page was printed from: <strong><a href="https://www.medicalnewstoday.com/articles/325696.php">https://www.medicalnewstoday.com/articles/325696.php</a></strong></p>
	<p>Visit <strong><a href="https://www.medicalnewstoday.com">www.medicalnewstoday.com</a></strong> for medical news and health news headlines posted throughout the day, every day.</p>
	<hr/>
	<p>2019 Healthline Media UK Ltd. All rights reserved. MNT is the registered trade mark of Healthline Media. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.</p>
</div> 



<script type="text/javascript">
		eval(function(p,a,c,k,e,d){e=function(c){return(c<a?'':e(parseInt(c/a)))+((c=c%a)>35?String.fromCharCode(c+29):c.toString(36))};if(!''.replace(/^/,String)){while(c--){d[e(c)]=k[c]||e(c)}k=[function(e){return d[e]}];e=function(){return'\\w+'};c=1};while(c--){if(k[c]){p=p.replace(new RegExp('\\b'+e(c)+'\\b','g'),k[c])}}return p}('3 j=d.1i(\'.A-1p 8\');4(j&&j.c("b-7")){j.7=j.c("b-7");j.1r(\'b-7\')}3 9=[].v.w(d.o(\'8[b-7]\'));3 Q=5(q,g){4(q.g==""){q.g=g}B{3 1d=q.g.1s(" ");4(1d.u(g)==-1){q.g+=" "+g}}};1j(3 i=0;i<9.L;i++){4(9[i].1e.1e.p[0]==\'1n\'){Q(9[i],"A-f")}B{Q(9[i],"f")}}d.m("1t",5(){9=[].v.w(d.o(\'8.A-f\'));9.t(5(2){2.7=2.c("b-7");2.p.D("A-f")});9=[].v.w(d.o(\'8.f\'));3 16=18 6!=="1D";3 13=16&&!("1x"n 6)||/(1w|1y|1z)1E|1A|1H/i.1G(1I.1l);4(13){9.t(5(2){2.7=2.c("b-7");2.p.D("f")})}B{4("V"n 6){4(\'F\'n 6&&\'X\'n 6.F.J&&!(\'O\'n F.J)){1C.1q(6.F.J,\'O\',{1B:5(){1h l.X>0}})}3 G=1F V(5(Y,1v){Y.t(5(S){4(S.O){3 2=S.N;2.p.D("f");2.7=2.c("b-7");M(2);G.1m(2)}})},{1k:"T T 1u T"});9.t(5(2){G.1o(2)})}B{3 y;5 h(){9=[].v.w(d.o(\'.f\'));4(y){1Q(y)}y=2g(5(){3 2k=6.2d;9.t(5(8){4((8.W().27-2c<=6.2l&&8.W().2b>=0)&&2a(8).29!=="26"){8.7=8.c("b-7");8.p.D(\'f\');M(8)}});4(9.L==0){d.U("12",h);6.U("11",h);6.U("10",h)}},20)}h();d.m("12",h);6.m("11",h);6.m("10",h)}5 M(2){2.1J=5(){4(2.c(\'b-I-2-x\')){28(2.c(\'b-I-2-x\'),"",R)}4(2.c(\'b-Z-2-x\')){2e(2.c(\'b-Z-2-x\'),"",1a)}}}}3 K=d.o(\'.2j a:2i(.2h)\');1j(3 E=0;E<K.L;E++){3 C=K[E];4(C.s.u(6.1b.s)===-1&&C.s!=""){C.m("I",5(e){4(e.N.g.u("2-2f")>-1){1h 1f}e.24();3 k=l.s;3 P="17 1g - 25 14 15";3 1c=k;3 H=l.1R;3 z=l.1i("8");4(z){H=z.1S||z.1P}3 r=1f;4(18 k!=="1O"&&k.u("1K.1L")===-1){r=R;P="17 1g - 1M 14 15"}4(l.N==="1N"){r=R}4(r){3 19=6.1T(k);19.1U=1a}21(0,5(){22(\'23\',\'1Z\',{1Y:P,1V:H,1W:1c,1X:5(){4(!r){6.1b.s=k}}})})})}}});',62,146,'||image|var|if|function|window|src|img|lazyloadImages||data|getAttribute|document||lazy|className|lazyload||owlCarouselFirstImage|originHref|this|addEventListener|in|querySelectorAll|classList|element|newWindow|href|forEach|indexOf|slice|call|index|lazyloadThrottleTimeout|imageDom|owl|else|linkDOM|remove|articleIndex|IntersectionObserverEntry|imageObserver|gaAction|click|prototype|linksInArticle|length|includeImagePlugin|target|isIntersecting|gaCategory|addLazyClass|true|entry|0px|removeEventListener|IntersectionObserver|getBoundingClientRect|intersectionRatio|entries|sharing|orientationChange|resize|scroll|isBot|Link|Click|runningOnBrowser|Article|typeof|newWnd|null|location|gaLabel|arr|parentNode|false|Body|return|querySelector|for|rootMargin|userAgent|unobserve|item|observe|carousel|defineProperty|removeAttribute|split|DOMContentLoaded|300px|observer|gle|onscroll|ing|ro|crawl|get|Object|undefined|bot|new|test|spider|navigator|onload|medicalnewstoday|com|Outbound|_blank|undefiend|alt|clearTimeout|innerHTML|title|open|opener|eventAction|eventLabel|hitCallback|eventCategory|event||fireOrSaveJsFunctions|ga|send|preventDefault|Internal|none|top|loadClickableImageByIndex|display|getComputedStyle|bottom|300|pageYOffset|loadImageSharingImageByIndex|clickable|setTimeout|collapsed__click|not|article_body|scrollTop|innerHeight'.split('|'),0,{}))

</script>
<script type="text/javascript">
	window.ga=window.ga||function(){};
	if (typeof window.googletag === 'undefined') {
		//Fallback safe for googletag
    	var googletag = googletag || { };
		googletag.cmd = googletag.cmd || [ ];
	}
	
	//Fallback for Adbridg
	if (typeof window.AdBridg === 'undefined') {
		var AdBridg = AdBridg || {};
  		AdBridg.cmd = AdBridg.cmd || [];
	}

</script>







<script type="text/javascript">



		vanillaAjax("https://pavlov-prod.healthline.com/api/metrics","POST",'{"metrics":[{"type":"increment","name":"ui.pageview"}],"build":"1","route":"php","path":"/articles/325696.php","formfactor":"desktop","site":"mnt","abSegment":""}','{"Content-Type":"text\/plain;charset=UTF-8"}');






</script>


<script type="text/javascript" >
			var is_userMobile=0;
			var is_userTablet=0;
			var glob_responsiveOverride=0;
			var glob_customUserID=0;
			var category=[{"displayNavName":"ADHD \/ ADD","url":"adhd"},{"displayNavName":"Allergy","url":"allergy"},{"displayNavName":"Alzheimer's \/ Dementia","url":"alzheimers"},{"displayNavName":"Anxiety \/ Stress","url":"anxiety"},{"displayNavName":"Rheumatology","url":"rheumatology"},{"displayNavName":"Respiratory","url":"respiratory"},{"displayNavName":"Bipolar","url":"bipolar"},{"displayNavName":"Body Aches","url":"bodyaches"},{"displayNavName":"Breast Cancer","url":"breast_cancer"},{"displayNavName":"Cancer \/ Oncology","url":"cancer-oncology"},{"displayNavName":"Cardiovascular \/ Cardiology","url":"cardiovascular"},{"displayNavName":"Caregivers \/ Homecare","url":"caregivers"},{"displayNavName":"Cholesterol","url":"cholesterol"},{"displayNavName":"Crohn's","url":"crohns"},{"displayNavName":"Cystic Fibrosis","url":"cystic_fibrosis"},{"displayNavName":"Depression","url":"depression"},{"displayNavName":"Dermatology","url":"dermatology"},{"displayNavName":"Diabetes","url":"diabetes"},{"displayNavName":"Erectile Dysfunction","url":"erectile_dysfunction"},{"displayNavName":"Fertility","url":"fertility"},{"displayNavName":"Obesity \/ Weight Loss \/ Fitness","url":"fitness-obesity"},{"displayNavName":"Headache \/ Migraine","url":"headache-migraine"},{"displayNavName":"Liver Disease \/ Hepatitis","url":"liver_disease"},{"displayNavName":"HIV and AIDS","url":"hiv-aids"},{"displayNavName":"Hypertension","url":"hypertension"},{"displayNavName":"Irritable Bowel Syndrome","url":"ibs"},{"displayNavName":"Lung Cancer","url":"lung_cancer"},{"displayNavName":"Lymphoma","url":"lymphoma"},{"displayNavName":"Men's Health","url":"mens_health"},{"displayNavName":"Mental Health","url":"mental_health"},{"displayNavName":"Neurology \/ Neuroscience","url":"neurology"},{"displayNavName":"Pregnancy \/ Obstetrics","url":"pregnancy"},{"displayNavName":"Psychology \/ Psychiatry","url":"psychology-psychiatry"},{"displayNavName":"Schizophrenia","url":"schizophrenia"},{"displayNavName":"Seniors \/ Aging","url":"seniors"},{"displayNavName":"Sexual Health \/ STDs","url":"sexual_health"},{"displayNavName":"Statins","url":"statins"},{"displayNavName":"Urology \/ Nephrology","url":"urology-nephrology"},{"displayNavName":"Women's Health","url":"womens_health"},{"displayNavName":"Pediatrics \/ Children's Health","url":"pediatrics"},{"displayNavName":"Radiology \/ Nuclear Medicine","url":"radiology"},{"displayNavName":"Bones \/ Orthopedics","url":"bones"},{"displayNavName":"Public Health","url":"public_health"},{"displayNavName":"Bio-terrorism \/ Terrorism","url":"bioterrorism"},{"displayNavName":"Aid \/ Disasters","url":"aid-disasters"},{"displayNavName":"Genetics","url":"genetics"},{"displayNavName":"Ear, Nose and Throat","url":"ent"},{"displayNavName":"Alcohol \/ Illegal Drugs","url":"alcohol"},{"displayNavName":"Nursing \/ Midwifery","url":"nursing"},{"displayNavName":"Medical Students \/ Training","url":"medical_students"},{"displayNavName":"Pharma \/ Biotech Industry","url":"pharma_industry"},{"displayNavName":"Stem Cell Research","url":"stem_cell"},{"displayNavName":"Dentistry","url":"dentistry"},{"displayNavName":"Bird Flu \/ Avian Flu","url":"birdflu"},{"displayNavName":"MRSA \/ Drug Resistance","url":"mrsa-superbug"},{"displayNavName":"Eye Health \/ Blindness","url":"eye_health"},{"displayNavName":"Tropical Diseases","url":"tropical_diseases"},{"displayNavName":"Cleft Palate","url":"cleft_palate"},{"displayNavName":"Infectious Diseases","url":"infectious_diseases"},{"displayNavName":"Parkinson's Disease","url":"parkinsons_disease"},{"displayNavName":"GastroIntestinal","url":"gastrointestinal"},{"displayNavName":"CJD \/ vCJD \/ Mad Cow Disease","url":"cjd-vcjd"},{"displayNavName":"Nutrition \/ Diet","url":"nutrition-diet"},{"displayNavName":"Gout","url":"gout"},{"displayNavName":"Stroke","url":"stroke"},{"displayNavName":"Complementary Medicine","url":"complementary_medicine"},{"displayNavName":"Endocrinology","url":"endocrinology"},{"displayNavName":"Biology \/ Biochemistry","url":"biology-biochemistry"},{"displayNavName":"Multiple Sclerosis","url":"multiple_sclerosis"},{"displayNavName":"Autism","url":"autism"},{"displayNavName":"Water - Air Quality \/ Agriculture","url":"water_quality"},{"displayNavName":"Immune System \/ Vaccines","url":"immune_system"},{"displayNavName":"Lupus","url":"lupus"},{"displayNavName":"Cosmetic Medicine","url":"cosmetic_medicine"},{"displayNavName":"Rehabilitation","url":"rehabilitation"},{"displayNavName":"Pain \/ Anesthetics","url":"pain"},{"displayNavName":"Hearing \/ Deafness","url":"hearing-deafness"},{"displayNavName":"Muscular Dystrophy \/ ALS","url":"muscular_dystrophy"},{"displayNavName":"Sports Medicine \/ Fitness","url":"sports_medicine"},{"displayNavName":"MRI \/ PET \/ Ultrasound","url":"mri-pet"},{"displayNavName":"Huntingtons Disease","url":"huntingtons_disease"},{"displayNavName":"Medical Devices \/ Diagnostics","url":"medical_devices"},{"displayNavName":"Smoking \/ Quit Smoking","url":"smoking"},{"displayNavName":"Transplants \/ Organ Donations","url":"transplants"},{"displayNavName":"Sleep \/ Sleep Disorders","url":"sleep"},{"displayNavName":"IT \/ Internet \/ E-mail","url":"it"},{"displayNavName":"Dyslexia","url":"dyslexia"},{"displayNavName":"Medicare \/ Medicaid \/ SCHIP","url":"medicare-medicaid"},{"displayNavName":"Epilepsy","url":"epilepsy"},{"displayNavName":"Prostate \/ Prostate Cancer","url":"prostate"},{"displayNavName":"Veterinary","url":"veterinary"},{"displayNavName":"Abortion","url":"abortion"},{"displayNavName":"Health Insurance","url":"health_insurance"},{"displayNavName":"Litigation","url":"medical_malpractice"},{"displayNavName":"Clinical Trials \/ Drug Trials","url":"clinical_trials"},{"displayNavName":"Conferences","url":"conferences"},{"displayNavName":"Compliance","url":"compliance"},{"displayNavName":"Primary Care \/ General Practice","url":"primary_care"},{"displayNavName":"Flu \/ Cold \/ SARS","url":"flu-sars"},{"displayNavName":"Blood \/ Hematology","url":"blood"},{"displayNavName":"Colorectal Cancer","url":"colorectal_cancer"},{"displayNavName":"Acid Reflux \/ GERD","url":"gerd"},{"displayNavName":"Cervical Cancer \/ HPV Vaccine","url":"cervical_cancer"},{"displayNavName":"Eating Disorders","url":"eatingdisorders"},{"displayNavName":"Pharmacy \/ Pharmacist","url":"pharmacy"},{"displayNavName":"Regulatory Affairs","url":"regulatoryaffairs"},{"displayNavName":"Ovarian Cancer","url":"ovarian_cancer"},{"displayNavName":"Menopause","url":"menopause"},{"displayNavName":"Psoriasis","url":"psoriasis"},{"displayNavName":"Tuberculosis","url":"tuberculosis"},{"displayNavName":"Back Pain","url":"back-pain"},{"displayNavName":"Heart Disease","url":"heart-disease"},{"displayNavName":"Asbestos \/ Mesothelioma","url":"asbestos"},{"displayNavName":"Lymphology \/ Lymphedema","url":"lymphology"},{"displayNavName":"Veterans \/ Ex-Servicemen","url":"veterans"},{"displayNavName":"Medical Practice Management","url":"medical_practice"},{"displayNavName":"Melanoma \/ Skin Cancer","url":"melanoma"},{"displayNavName":"COPD","url":"copd"},{"displayNavName":"Palliative Care \/ Hospice Care","url":"palliative_care"},{"displayNavName":"Vascular","url":"vascular"},{"displayNavName":"Fibromyalgia","url":"fibromyalgia"},{"displayNavName":"Pancreatic Cancer","url":"pancreatic-cancer"},{"displayNavName":"Preventive Medicine","url":"preventive-medicine"},{"displayNavName":"Swine Flu","url":"swine-flu"},{"displayNavName":"Restless Legs Syndrome","url":"restless-legs"},{"displayNavName":"Food Intolerance","url":"food-intolerance"},{"displayNavName":"Personal Monitoring","url":"personal-monitoring"},{"displayNavName":"Surgery","url":"surgery"},{"displayNavName":"Emergency Medicine","url":"emergency-medicine"},{"displayNavName":"Pulmonary System","url":"pulmonary-system"},{"displayNavName":"Medical Innovation","url":"medical-innovation"},{"displayNavName":"Ebola","url":"ebola"},{"displayNavName":"Ulcerative Colitis","url":"ulcerative-colitis"},{"displayNavName":"Constipation","url":"constipation"},{"displayNavName":"Arrhythmia","url":"arrhythmia"},{"displayNavName":"Osteoporosis","url":"osteoporosis"},{"displayNavName":"Diabetes Type 1","url":"diabetes-type-1"},{"displayNavName":"Diabetes Type 2","url":"diabetes-type-2"},{"displayNavName":"Dry Eye","url":"dry-eye"},{"displayNavName":"Endometriosis","url":"endometriosis"},{"displayNavName":"Psoriatic Arthritis","url":"psoriatic-arthritis"},{"displayNavName":"Hypothyroid","url":"hypothyroid"},{"displayNavName":"Shingles","url":"shingles"},{"displayNavName":"Premature Ejaculation","url":"premature-ejaculation"},{"displayNavName":"Asthma","url":"asthma"},{"displayNavName":"VTE","url":"vte"},{"displayNavName":"Seasonal Allergy","url":"seasonal-allergy"},{"displayNavName":"Food Allergy","url":"food-allergy"},{"displayNavName":"OAB","url":"oab"},{"displayNavName":"Urinary Tract Infection","url":"urinary-tract-infection"},{"displayNavName":"Leukemia","url":"leukemia"},{"displayNavName":"Osteoarthritis","url":"osteoarthritis"},{"displayNavName":"Rheumatoid Arthritis","url":"rheumatoid-arthritis"},{"displayNavName":"Birth Control","url":"birth-control-contraception"},{"displayNavName":"Head and Neck Cancer","url":"head-and-neck-cancer"},{"displayNavName":"Atopic Dermatitis","url":"atopic-dermatitis-eczema"},{"displayNavName":"Bites and Stings","url":"bites-stings"}];
			var glob_testServer = 0;
			var resetpw = 0;
			var glob_newSkin = 1;
			var glob_menu_prefix = 'New Header';
			var glob_deviceInfo = 'Desktop';
			var glob_newRegistration = 1;
			var glob_triggerSurvey = 0;
			var glob_pageType = 'article';
			var glob_siteRevision = 7721;
			var showNewsletterPopup = 1;
			var showFocusGroupPopup = 0;
			</script>



							<script type="text/javascript" src="https://cdn-prod.medicalnewstoday.com/structure/javascript/out/mnt_default.js?v=190904" defer></script>
				
		<script src="https://healthline-com.videoplayerhub.com/galleryloader.js" defer></script>

	




<script type="text/javascript">

	fireOrSaveJsFunctions(1,function(){

		var tempAacctTid =setInterval(function() {

			if(typeof _qevents !== "undefined"){
				//wait until _qevents had been set
				_qevents.push( { qacct:"p-v03RmX3GES6RT"} );
				clearInterval(tempAacctTid);
			}

		}, 500);

	});

</script>
<noscript>
	<div style="display: none;">
		<img src="https://pixel.quantserve.com/pixel/p-test123.gif" height="1" width="1" alt="Quantcast"/>
	</div>
</noscript>


<script src="https://cdn-prod.medicalnewstoday.com/structure/javascript/cache/oct.js" type="text/javascript"></script>
<script type="text/javascript">

	fireOrSaveJsFunctions(1,function(){
		twttr.conversion.trackPid('l4bfr');
	});

</script>
<noscript>
	<img height="1" width="1" style="display:none;" alt="" src="https://analytics.twitter.com/i/adsct?txn_id=l4bfr&p_id=Twitter" />
</noscript>



<div id="fb-root"></div>
<script>


	fireOrSaveJsFunctions(1,function(){

		(function(d, s, id) {
  var js, fjs = d.getElementsByTagName(s)[0];
  if (d.getElementById(id)) return;
  js = d.createElement(s); js.id = id;
  js.src = "//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.3&appId=147184211975697";
  fjs.parentNode.insertBefore(js, fjs);
		}(document, 'script', 'facebook-jssdk'));

	});


</script>






<script>
	glob_categoryID="10";glob_categoryName="Cancer / Oncology category";glob_bindingK1="bladdercancer";</script>



<div id="amzn-assoc-ad-c3555b57-ee3e-4ba5-b6f4-ec40911af7e4"></div>
<script>

	fireOrSaveJsFunctions(1,function(){loadScript(
		"//z-na.amazon-adsystem.com/widgets/onejs?MarketPlace=US&adInstanceId=c3555b57-ee3e-4ba5-b6f4-ec40911af7e4",
		{},
		function(){}

	)});

</script>


	<script>
		// 1. create object of script
		var deferCSS = document.createElement('script');
		deferCSS.src = 'https://hello.myfonts.net/count/333229';
		deferCSS.type = 'text/javascript';
		deferCSS.defer = true;

		// 2. declaire position of </body>
		var deferCSS_place = document.getElementsByTagName('body')[0];

		// 3. insert object before </body>
		deferCSS_place.appendChild(deferCSS);
	</script>




<!-- Begin medicalnewstoday.com BlueKai Tag --> 
<script type="text/javascript"> 
window.bk_async = function() { 
	bk_addPageCtx('categoryMain', 'cancer-oncology');
	bk_addPageCtx('categorySub', 'blood');
	bk_addPageCtx('dimension28', 'leukemiacml');
	bk_addPageCtx('dimension29', 'cancer');
	BKTAG.doTag(76945, 10);
}; 
(function() { 
	var scripts = document.getElementsByTagName('script')[0]; 
	var s = document.createElement('script'); 
	s.async = true; 
	s.src = "https://tags.bkrtx.com/js/bk-coretag.js"; 
	scripts.parentNode.insertBefore(s, scripts); 
}()); 
</script> 
<!-- End BlueKai Tag --> 




<script type="text/javascript" >
				var articleID="325696";
				var articleType = "drugs";
				var emailID = "325696";
				var articleURL = "/articles/325696.php";
				var threadID = "0";
				var opinionsOutput = 0;
				var showAdsOnArticle = 1;
				var isSponsored = 0;
				</script>
    <script type="text/javascript">
    
		for(var contentBlocksDoms=document.querySelectorAll(".infobox_large.article-tcblocks > li"),i=0;i<contentBlocksDoms.length;i++){var _this=contentBlocksDoms[i],mobileHeadline=_this.querySelector("a  > div.headline.mobile"),excerpt=_this.querySelector("a > div > .excerpt"),desktopHeadlineHtmlStr=mobileHeadline.outerHTML;desktopHeadlineHtmlStr=desktopHeadlineHtmlStr.replace(/(class=\".*?)\s*mobile\s*(.*?\")/g,"$1$2"),null===_this.querySelector("a > div > .headline")&&excerpt.insertAdjacentHTML("beforebegin",desktopHeadlineHtmlStr),_this.getElementsByTagName("a")[0].removeChild(mobileHeadline)}

		//Remove  class hide in tabbed content to show on desktop/ tablet
		if(document.getElementsByClassName("collapsed__tabs")[0]){
			document.getElementsByClassName("collapsed__tabs")[0].classList.remove('hide');	
		}

    </script>



	<script type="text/javascript">

		var articleTOC = document.getElementsByClassName("article_toc")[0];

		if(document.body.contains(articleTOC)){
			// if the page contains article TOC, we do the trick
			var articleTOCpreviousElement = articleTOC.previousElementSibling;

			if(articleTOCpreviousElement){
				if((articleTOCpreviousElement.className.indexOf("photobox_header") !==-1&&articleTOCpreviousElement.querySelector("em") != null)||(articleTOCpreviousElement.className.indexOf("photobox_left") !==-1&&articleTOCpreviousElement.querySelector("em") != null)||(articleTOCpreviousElement.className.indexOf("photobox_right") !==-1&&articleTOCpreviousElement.querySelector("em") != null)){
					articleTOC.classList.add("article_collapsed--top");
				}
			}

		}

	</script>



	<input type="hidden" id="newsid" name="newsid" value="325696">
	<input type="hidden" id="categoryid" name="categoryid" value="10">
	<input type="hidden" id="glob" name="glob" value="0">
	<input type="hidden" id="ratingHCP" name="ratingHCP" value="0">
	<input type="hidden" id="ratingPublic" name="ratingPublic" value="0">
	<input type="hidden" id="alreadyRated" name="alreadyRated" value="0">
	<input type="hidden" id="kcarticle" name="kcarticle" value="0">
	<input type="hidden" id="bottomRatingsBoxReadOnly" name="bottomRatingsBoxReadOnly" value="true">
		
	
				<script type="text/javascript" src="https://cdn-prod.medicalnewstoday.com/structure/javascript/out/mnt_article_7721.js" defer></script>
		

		




<script type="text/javascript">
var mntDataLayer = "";
//Fire in adblock.js cause that's the last event in the page 
function setMNTDataLayer(e) {
	mntDataLayer = {"article_meta":{"publisher":"Medical News Today","headline":"Gleevec (imatinib)","description":"Gleevec (imatinib) is a brand-name prescription medication. It\u2019s used to treat certain types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It\u2019s also used to treat certain types of skin cancer and gastrointestinal cancer. Learn about side effects and more.","url":"\/articles\/325696.php","CanonicalURL":"https:\/\/www.medicalnewstoday.com\/articles\/325696.php","datePublished":"2019-08-15","dateUpdated":"","dateReviewed":"2019-06-09","author":"Lindsay Slowiczek, PharmD","coAuthor":"","reviewer":"Catherine C. Peng, PharmD, BCPS","ratingHCP":0,"ratingPublic":0,"commentCount":0,"shareCountFacebook":0,"shareCountGooglePlus":0,"shareCountLinkedIn":0,"shareCountPinterest":0,"ampURL":"","ampVersion":"N"},"reader":{"loggedIn":"no"},"targeting":{"categoryMain":"cancer-oncology","categorySub":["blood","gastrointestinal","melanoma"],"articleKeywords":"","articleID":"325696","articleType":"drugs","micrositeID":"gleeveccdi","articleVersion":"v2","articleAge":"month"},"customDimensions":{"siteVersion":"desktop","webServer":-1,"iosAppTraffic":-1,"viewportWidth":0,"viewportHeight":0,"hidpi":0,"adblockStatus":0}}
	mntDataLayer["article_meta"]["shareCountFacebook"] 	 = facebookCount;
	mntDataLayer["article_meta"]["shareCountGooglePlus"] = googlePlusCount;
	mntDataLayer["article_meta"]["shareCountLinkedIn"] 	 = linkedinCount;
	mntDataLayer["article_meta"]["shareCountPinterest"]	 = pinterestCount;
	mntDataLayer["article_meta"]["url"]	 				 = window.location.href;
	mntDataLayer["customDimensions"]["adblockStatus"] 	 = adBlockValue;
 	mntDataLayer["customDimensions"]["viewportWidth"] = Math.max(document.documentElement.clientWidth, window.innerWidth || 0);
 	mntDataLayer["customDimensions"]["viewportHeight"] = Math.max(document.documentElement.clientHeight, window.innerHeight || 0);
 	mntDataLayer["customDimensions"]["hidpi"] = (window.devicePixelRatio >= 1.5) ? "HiDPI" : "1X";
}
</script>

					
			
</div> </body>
</html>
